



## Review paper

# Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review

Sara Meirinho <sup>a</sup>, Márcio Rodrigues <sup>a,b</sup>, Ana Fortuna <sup>c,d</sup>, Amílcar Falcão <sup>c,d</sup>, Gilberto Alves <sup>a,\*</sup>

<sup>a</sup> Faculty of Health Sciences, Health Sciences Research Center, University of Beira Interior (CICS UBI), 6200-506, Covilhã, Portugal

<sup>b</sup> Research Unit for Inland Development, Polytechnic Institute of Guarda (UDI-IPG), 6300-654, Guarda, Portugal

<sup>c</sup> Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra, 3000-548, Coimbra, Portugal

<sup>d</sup> Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal



## ARTICLE INFO

## Article history:

Received 27 February 2020

Received in revised form

26 October 2020

Accepted 17 November 2020

Available online 28 November 2020

## Keywords:

Bioanalysis

Liquid chromatography

Perampanel

Retigabine

Rufinamide

Stiripentol

## ABSTRACT

The new antiepileptic drugs perampanel, retigabine, rufinamide and stiripentol have been recently approved for different epilepsy types. Being them an innovation in the antiepileptics armamentarium, a lot of investigations regarding their pharmacological properties are yet to be performed. Besides, considering their broad anticonvulsant activities, an extension of their therapeutic indications may be worthy of investigation, especially regarding other seizure types as well as other central nervous system disorders. Although different liquid chromatographic (LC) methods coupled with ultraviolet, fluorescence, mass or tandem-mass spectrometry detection have already been developed for the determination of perampanel, retigabine, rufinamide and stiripentol, new and more cost-effective methods are yet required. Therefore, this review summarizes the main analytical aspects regarding the liquid chromatographic methods developed for the analysis of perampanel, retigabine (and its main active metabolite), rufinamide and stiripentol in biological samples and pharmaceutical dosage forms. Furthermore, the physicochemical and stability properties of the target compounds will also be addressed. Thus, this review gathers, for the first time, important background information on LC methods that have been developed and applied for the determination of perampanel, retigabine, rufinamide and stiripentol, which should be considered as a starting point if new (bio)analytical techniques are aimed to be implemented for these drugs.

© 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Epilepsy is one of the most prevalent neurological diseases worldwide, affecting nearly 1%–2% of the population [1–4]. Currently, there are more than 20 antiepileptic drugs (AEDs) available for clinical use, which are usually divided into three different generations. First-generation AEDs present several drawbacks such as narrow therapeutic indices, complex

pharmacokinetic profiles, saturable metabolism, high plasma protein binding (PPB), and high potential for drug interactions, and may induce anticonvulsant hypersensitivity syndrome. However, the cumulative experience in its clinical application is extensive, this being the reason why these AEDs are still the first choice for many epilepsy disorders [5–9]. To overcome the aforementioned disadvantages and to achieve higher efficacy and better tolerability, second-generation AEDs were then developed, followed by third-generation AEDs, which began with the approval of lacosamide in 2008 [5,6,8]. Besides the improvements in their pharmacological profiles, third-generation AEDs also present some new chemical structures that allow them to act by new mechanisms of action, interact with different therapeutic

Peer review under responsibility of Xi'an Jiaotong University.

\* Corresponding author.

E-mail address: [gilberto@fcsaude.ubi.pt](mailto:gilberto@fcsaude.ubi.pt) (G. Alves).

targets and modulate different pathways of neuronal excitability that were not covered by first- and second-generation AEDs [5,10–12]. Thus, to increase therapeutic effectiveness, improve tolerability and decrease toxicity, the introduction of third-generation AEDs as adjunctive therapy to patients already treated with other types of AEDs is frequent [6]. Examples of AEDs with such characteristics are shown in Fig. 1 and include retigabine (RTG) (known as ezogabine in USA), rufinamide (RFM), stiripentol (STP) and perampanel (PER). RFM and STP are both classified as orphan drugs since their therapeutic indications are specific for treating epileptic syndromes with a very low prevalence in population. Specifically, RFM is indicated to treat a severe, chronic, and multiple drug-resistance epileptic encephalopathy mostly characterized by the occurrence of multiple seizure types so called Lennox-Gastaut syndrome. It is also used in the treatment of super-refractory tonic-clonic status epilepticus and as adjunctive treatment of partial seizures in adults and adolescents [13–15]. On the other hand, STP is indicated as adjunctive therapy with clobazam and valproic acid to treat Dravet syndrome not only in children, but also during adolescence and adulthood [16,17]. This syndrome, also known as severe myoclonic epilepsy of infancy, is another progressive epileptic encephalopathy [18–21]. Contrary to STP and RFM, RTG and PER are broadly used as adjunctive therapy in different types of epileptic seizures [2,5,22–26]. Recently, clinical evidence also shows that PER is effective in monotherapy for the treatment of focal seizures [4,27].

Although the new AEDs present a better safety profile, they are also associated with adverse and toxic effects, most of them being dose-dependent [6,7,18,26]. Hence, even though the therapeutic reference range for plasma/serum concentrations of these new AEDs is presently under debate, it is indisputable the important role that therapeutic drug monitoring (TDM) plays as a therapeutic guidance because epilepsy treatment is mostly prophylactic. Therefore, the application of TDM to these new AEDs is useful and, sometimes, critical [25,28–31]. However, to accurately apply TDM, the measurement of RFM, STP, RTG and PER concentrations in plasma, serum or whole blood must be performed with validated bioanalytical methods. Though, to correlate AEDs concentrations with respective clinical effects, the concentration of drugs in brain may still be more determinant than that in blood. Nevertheless, as the drug quantification in patients' brains is not feasible, it is of great importance to perform non-clinical

pharmacokinetic and pharmacodynamic assays in order to correlate, as accurately as possible, the plasma drug concentrations with drug concentrations in brain. For that, the development of methods for quantification of these AEDs in several laboratory animals' matrices used to perform these studies becomes mandatory [30,32]. Considering the new AEDs, there is also evidence of important interindividual variability in their pharmacokinetics, which is mostly resultant from differences in the hepatic metabolism. In fact, pharmacokinetic properties and their influence on the pharmacodynamics must be investigated more deeply, particularly for new AEDs, such as RTG, RFM, STP and PER, since the information currently available is still scarce. Thus, to successfully and accurately obtain this evidence, drug concentration in biological samples must be measured and, for that reason, bioanalysis is crucial. In this context, it is important to use fully validated bioanalytical methods to generate reliable data. In addition, some analytical methods have also been developed for the quantification of the selected AEDs in pharmaceutical formulations, which is fundamental during quality control process of medicinal products. Therefore, this work aims to provide a comprehensive and critical review of some pharmacokinetic aspects of interest from a bioanalytical perspective for RFM, RTG, STP and PER, as well as to gather, for the first time, sufficient background information about several techniques involving liquid chromatography (LC) that have been reported for the determination of those AEDs in both biological matrices and pharmaceutical formulations. All these gathered data, herein discussed in an integrated manner, will be useful for supporting the development and validation of new and improved analytical methods for the determination of these target compounds (i.e., RFM, RTG, STP and PER).

## 2. Pharmacokinetic properties

In general, third-generation AEDs have a more favorable pharmacokinetic profile than the old ones [5,31]. The main pharmacokinetic properties of RTG, RFM, STP and PER in humans are summarized in Table 1 [2,4,18–20,22,23,25,33–39].

Except for RTG, which shows an oral bioavailability of 60%, all the other three AEDs have a high oral bioavailability ( $\geq 85\%$ ), with PER presenting the ideal value of approximately 100%. On average, the time to reach maximum plasma concentration ( $t_{max}$ ) after oral administration is shorter for both RTG and PER, than that for STP and RFM [2,4,15,23,25,36,38–40]. Food is also responsible for RTG and PER  $t_{max}$  delay up to 2 h, but for both drugs, the extent of absorption and their bioavailability are not substantially affected [2,4,18,22,23,38,39]. In the case of RFM and STP, they are recommended to be administered with food, because it is demonstrated that food intake not only increases the bioavailability of RFM [15,36], but also protects STP from fast degradation in the acidic environment found on an empty stomach [20]. Actually, STP degradation in acidic conditions was demonstrated during a stability study that used 0.5 M hydrochloric acid, a similar condition of the stomach environment [41]. Regarding PPB, there are some differences between the four AEDs (Table 1). STP and PER are particularly characterized by high PPB values of 99% and 95% respectively, being for that important to take these values into consideration when determination of plasma concentrations is performed, particularly during TDM studies and therapeutic reference ranges optimization [5,19,32,38,42]. By analyzing Table 1, it is also evident that there are different characteristics in relation to apparent volume of distribution ( $V_d$ ) and elimination half-life ( $t_{1/2el}$ ). RTG shows a larger  $V_d$  comparatively with PER and RFM [22,23]. Regarding RFM and PER  $V_d$  values, it can be expected that




Fig. 1. Chemical structures of retigabine, rufinamide, stiripentol and perampanel.

**Table 1**  
Main pharmacokinetic properties of the new antiepileptic drugs stiripentol (STP), retigabine (RTG), rufinamide (RFM) and perampanel (PER) in humans.

Drug	F <sub>po</sub> (%)	PPB (%)	t <sub>max</sub> (h)	t <sub>SS</sub> (days)	t <sub>1/2el</sub> (h)	V <sub>d</sub> (L/kg)	Active metabolite	Main excretion routes	Linear PK	Food effect	Reference range (mg/L)	Refs.
STP	≥90	99	1.5–3	1–2	4.5–13	Variable	No	Renal (70% as metabolites) Feces (13%–24% as unchanged)	No; systemic exposure increases and clearance decreases with higher doses	Food avoids degradation in acidic environment	4–22	[18–20,25,33,34]
RTG	60	80	0.5–2	1–2	8	6–8.7	<i>N</i> -acetyl-retigabine	Renal (85%) Feces (14%)	Yes	Food increases C <sub>max</sub> , but not AUC; t <sub>max</sub> increase up to 2 h	Not established	[2,22,23,33,35]
RFM	≥85	26–35	4–6	2	6–12	0.7–1.1	No	Renal (84.7%)	No; C <sub>max</sub> and AUC increase in a less than dose-proportional manner	Food increases C <sub>max</sub> and AUC	4–31	[2,18,25,33,36]
PER	≈100	95	0.5–2.5	10–19	105	1.1	No	Feces (70% as metabolites) Renal (30%)	Yes	Food increases t <sub>max</sub> up to 2 h, but not absorption extent	0.086–1	[4,25,33,37–39]

AUC: area under the curve; C<sub>max</sub>: peak plasma drug concentration; F<sub>po</sub>: oral bioavailability; PER: perampanel; PK: pharmacokinetics; PPB: plasma protein binding; RFM: rufinamide; RTG: retigabine; STP: stiripentol; t<sub>1/2el</sub>: elimination half-life; t<sub>max</sub>: time to reach maximum plasma concentration; t<sub>SS</sub>: time to reach steady-state; V<sub>d</sub>: apparent volume of distribution.

both present similar body distribution patterns [15,18,36,40]. In case of STP, its V<sub>d</sub> values were found to be variable, probably as a result of its non-linear pharmacokinetics, its strong PPB and its complex and extensive metabolism [18,20]. In fact, as illustrated in Fig. S1, STP extensive hepatic metabolism involves four different metabolic pathways (i.e., glucuronidation, oxidation of the methylenedioxy ring system, hydroxylation of *t*-butyl group, and conversion of the allylic alcohol chain to an isomeric 3-pentanone structure) [19,34,42–45]. Similarly to STP, PER also presents an extensive hepatic metabolism (Table 1) mainly mediated by CYP3A4 and CYP3A5 and, subsequently, by phase II reactions, originating inactive metabolites (Fig. S2) [38]. Contrary to STP and PER, RFM and RTG appear to have a less complex hepatic metabolism. In fact, clinical studies proved that RFM is not metabolized by CYPs, but rather by hydrolysis through carboxylesterases into inactive metabolites (Fig. S3) [36,40,46,47]. In the case of RTG, its metabolism is exclusively by phase II enzymes (Fig. S4) [2,26,35,48,49]. One of the metabolites formed during RTG metabolism is *N*-acetyl-retigabine, which has been a study target due to its potential anti-seizure activity revealed in animals, being for that a strong candidate for further pharmacologic studies [22,23,26,35,50–53]. However, one of the most challenging steps in the quantification of both RTG and the active metabolite *N*-acetyl-retigabine is the lability of *N*-glucuronide metabolites that are rapidly back-converted to RTG and *N*-acetyl-retigabine, creating a possible overestimation on its plasma concentration values. So, aiming to overcome this challenge, several works have been

published focusing not only on the study of RTG metabolism and *N*-acetyl-retigabine pharmacological activity, but also on this stability issue [50–53].

In order to achieve an appropriate seizure control and a suitable TDM, therapeutic reference ranges have already been proposed for STP, RFM and PER, but not yet for RTG (Table 1). For the implementation of TDM in clinical practice, the availability of therapeutic ranges and suitable bioanalytical methods for measurement of drug concentration levels are useful, allowing the adjustment of patient's medication regimens and the improvement of its therapeutic outcomes [25,28–30,33]. Validated bioanalytical methods are required to determine these AEDs concentrations in order to establish relationships between pharmacokinetic and pharmacodynamic properties, to better monitor patients' therapy with these new antiepileptics using TDM and to perform other valuable studies that can lead to an increase of the clinical and non-clinical knowledge regarding these new AEDs. Thus, this review will further focus on LC techniques already available in literature for RTG and *N*-acetyl-retigabine, RFM, STP and PER.

### 3. Physicochemical properties and drug stability

For the development of new bioanalytical methods, firstly we should consider the physicochemical properties of the target analytes. In case of RTG, RFM, STP and PER, up to date, the information available in literature regarding those properties is still scarce (Table 2) [37,38,41,54–65].

**Table 2**  
Physicochemical properties of stiripentol (STP), retigabine (RTG), rufinamide (RFM) and perampanel (PER).

Drug	MF	MW (g/mol)	pKa	Log P	Log D (pH 7.4)	Water solubility (mg/L)	0.1 M HCl solubility (mg/L)	Refs.
STP	C <sub>14</sub> H <sub>18</sub> O <sub>3</sub>	234.3	14.34 (strongest acidic); –3.1 (strongest basic)	3.53 or 2.94	2.80	49.2	Instable	[41,54–56]
RTG	C <sub>16</sub> H <sub>18</sub> FN <sub>3</sub> O <sub>2</sub>	303.3	13.6 (strongest acidic); 3.99 (strongest basic)	2.0 or 2.5	2.24	10.0	NR	[57–60]
RFM	C <sub>10</sub> H <sub>8</sub> F <sub>2</sub> N <sub>4</sub> O	238.2	12.69 (strongest acidic); –1.1 (strongest basic)	0.88	0.42	40.0	63	[61–63]
PER	C <sub>12</sub> H <sub>15</sub> N <sub>3</sub> O	349.4	3.24 (weak base)	3.7	2.92	5.6	470	[37,38,64,65]

Log D: distribution coefficient; Log P: octanol-water partition coefficient; MF: molecular formula; MW: molecular weight; NR: not reported; pKa: negative base-10 logarithm of the acid dissociation constant.

Considering their chemical structures, depicted in Fig. 1, the differences between the chemical groups that assembly these four AEDs are evident. PER is chemically a 2-(2-oxo-1-phenyl-5-pyridinyl-1,2-dihydropyridin-3-yl) benzonitrile hydrate, whose structure is responsible for the selective non-competitive antagonism of AMPA ionotropic glutamate receptors [38,64,66]. STP (4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol) is an aromatic allylic alcohol with no carbonyl or nitrogenous heterocycle in its structure that usually is responsible for the antiepileptic properties of the majority of AEDs. A particular feature of STP is the presence of a chiral center in C-3, resulting in a racemic mixture of R(+)-STP and S(-)-STP enantiomers, with the R(+)-STP presenting an anticonvulsant potency approximately 2.4-fold greater than that of the S(-)-enantiomer [34,41]. RFM (1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide) presents a triazole ring that can be responsible for its activity in different seizure types being, until now, the first AED with that unique chemical structure [15]. On the other hand, RTG (*N*-(2-amino-4-(4-fluorobenzylamino)phenyl carbamic acid ethyl ester) is an ester similar to the central analgesic flupirtine but structurally different from any other AEDs [49]. All four AEDs are weak bases [37,54,57–59,61], being their water solubility dependent on the pH values of the dissolution media. Therefore, a higher solubility is expected in acidic aqueous conditions instead of basic aqueous solutions, being this evident for PER and RFM, which have a higher solubility in a 0.1 M hydrochloric acid solution than in water (Table 2). Indeed, Rogawski and Hanada [64] stated that an explanation for PER fast absorption in the upper gastrointestinal tract is the rapid dissolution of the charged species in acidic conditions as gastric acid. PER, RTG and STP present a low water solubility, which is reflected by their high values of octanol/water partition coefficient (Log P) and distribution coefficient (Log D) measured in a buffer with a pH value of 7.4 [55,56,58,60,65,67] (Table 2). Therefore, a higher solubility of PER, RTG and STP in organic solvents is expected, being this a reasonable explanation to prepare their stock and working solutions using medium polarity solvents as acetonitrile [68–72], methanol [73,74] and ethanol [75–77]. In opposition, by analyzing RFM Log P and Log D values, this AED presents a lower lipophilic profile when compared with PER, RTG and STP [63]. This could be the reason why, in several studies, RFM powder dissolved in methanol is mentioned [62,78–81], a most polar solvent than acetonitrile, in a mixture of acetonitrile and water [82–85], or in a mixture of methanol and water or other polar solvents [86,87].

Another key factor to be considered in the development of new chromatographic methods is the stability of the analytes in biological samples and in stock and working solutions. Stability is usually related to compounds physicochemical properties, storage conditions, container systems, and the biological matrix itself [88,89]. The acceptance criteria for stability studies in biological samples are well described in the *Guideline on Bioanalytical Method Validation* [89] of the European Medicines Agency and in the recent *FDA Guidance for Industry: Bioanalytical Method Validation* [88]. Both guidelines refer that testing should cover the stock and working solutions stability as well as the analytes stability during sample collection, handling, storage and analysis. The accuracy of these assays at each concentration level should be within  $\pm 15\%$  of nominal concentrations. All the revised publications that performed stability studies adopted this acceptance criterion, and these studies are summarized in Table 3 [41,50,62,69–72,74–78,80–82,84,86,90–97].

Regarding short-term stability assays in biological matrices, for the studied AEDs, this period varied between 1.5 h [78] and one month [82], being the most common short-term stability studies performed after 24–72 h. In a particular case in which dried blood spots samples was used, la Marca et al. [82] exceptionally evaluated RFM stability after one month at room temperature, and proved

that this form of sampling could be kept in these storage conditions for at least one month. Stability studies under refrigerated storage conditions (e.g., 4 °C) are also frequently performed; STP, RTG, RFM and PER were shown to be stable after at least 24 h in those conditions. Besides, stability after three freeze-thaw cycles (24 h per cycle) and long-term stability tests performed at freezing temperatures in a time period ranging from 3 weeks to 376 days were also demonstrated for the four compounds. All storage conditions (sample type, storage time and temperature) applied in stability studies of the AEDs here studied are also described in Table 3.

Contrary to stability determination in biological matrices, only a few studies determined stability of PER, RTG, RFM and STP in stock and working solutions (Table 3). In several studies, the focus was to evaluate the AEDs stability in bulk and pharmaceutical forms and to investigate their degradation products and impurities [41,69,70,74,84,87,93,94,98], being that of great interest for the pharmaceutical industry. Stress degradation studies were carried out under acid and basic hydrolysis, oxidation, thermal and photolytic forced conditions. RTG proved to be sensitive to UV light exposure and susceptible to acidic and basic hydrolysis. Furthermore, like RFM, RTG can also be destroyed under oxidative conditions [69,74,84,94], while RFM and STP are degraded by acid hydrolysis [41,84,87]. In fact, STP instability in acidic conditions has practical implications, being mandatory to administer this drug orally with meals in order to avoid its acidic degradation by gastric acid [20]. In all cases, none of the degradation products showed to interfere with the retention time of the analyte.

#### 4. Sample preparation

Sample preparation procedures are critical and time-consuming steps applied to biological samples before the analysis of target analytes. Besides the great impact on nearly all the later analytical steps, sample preparation is essential since the presence of small molecules and macromolecules, salts and other matrix endogenous compounds may influence the detection of the analytes under investigation. Furthermore, those interferences can also be incompatible with the chromatographic system, particularly with chromatographic columns [99–101].

Before the beginning of sample pretreatment, it is common to add an internal standard (IS) to the sample. The use of an IS aims to compensate the loss of analytes during all steps of sample preparation and chromatographic procedures, leading to an increased accuracy and precision of the method [89,102,103]. The IS compound should preferentially have a chemical structure and physicochemical properties comparable to those of target drugs, must not be present in the original samples and not react or be destroyed by the sample components, mobile phase or stationary phase of the chromatographic columns. In some bioanalytical methods, the compounds used as IS are drugs clinically used to treat diseases which, in some cases, include epilepsy. In these cases, an extra care must be taken in order to understand whether the IS used is or is not present in the therapeutic regimens of the studied patients; if not, the method can be safely applied in sample analysis. Chemical structures of IS that have been used in bioanalytical assays for quantification of the target AEDs herein considered (i.e. STP, RTG, RFM and PER) are shown in Fig. S5. By comparing the chemical structures of STP, RTG, RFM and PER with the respective structures of the compounds used as IS for each AED analysis, the resemblance between them becomes quite evident. A good example of this is the use of flupirtine as IS in the determination of RTG in human plasma [91]. Regarding this matter, some studies have even used analogue compounds or labeled isotopes of the original analytes to increase the similarities, which is preferable to the use of other compounds [50,75,76,85,92,104].

**Table 3**  
Stability of stiripentol (STP), retigabine (RTG), rufinamide (RFM) and perampanel (PER) in organic solutions and in human and animal biological matrices.

Drug	Solution/matrix	Storage time	Storage temperature	Refs.
STP	Human plasma	4, 12 and 24 h 1, 2 and 3 months 3 freeze-thaw cycles	RT NR NR	[90]
STP <sup>a</sup>	Methanol	24, 48 and 72 h	25 °C	[41]
RTG	Human plasma	24, 48 and 72 h 24 h 60 days 3 freeze-thaw cycles	4 °C RT −30 °C NR	[91]
RTG <sup>a</sup>	Methanol	NR	NR	[74]
RTG, <i>N</i> -acetyl-retigabine <sup>b</sup>	Methanol	22 h 1 week	RT and −80 °C RT and −80 °C	[50]
RTG <sup>a</sup>	0.1% Triethylamine in water pH 2.5/acetonitrile (73:27, V/V)	3, 5, 8 and 24 h	RT and 4 °C	[69]
RTG	Acetonitrile	48 h	RT	[70]
<i>N</i> -acetyl-retigabine	Dog plasma	48 h post-preparation 12 days 3 freeze-thaw cycles	4 °C −70 °C NR	[92]
RFM	Mouse plasma, brain, liver and kidney	4 h 24 h 3 freeze-thaw cycles 30 days 24 h post-preparation	RT 4 °C −20 °C −20 °C RT	[81]
RFM	Rat plasma and brain	3 freeze-thaw cycles 27 days 24 h post-preparation	−20 °C −20 °C 15 °C	[80]
RFM	Dried plasma spots	1, 4, 7 and 10 days	25 °C	[86]
RFM	Human plasma	48 h post-preparation 3 freeze-thaw cycles 1.5 h	5–8 °C NR RT	[78]
RFM <sup>a</sup>	Water/acetonitrile (40:60, V/V)	NR	NR	[84]
RFM <sup>a</sup>	Methanol	24 h	25 °C	[93]
RFM <sup>c</sup>	Water/methanol (1:1, V/V)	24 h	70 °C in 0.1 M HCl 70 °C in 0.1 M NaOH	[87]
RFM <sup>a</sup>	Acetonitrile/tetrabutylammonium hydrogen sulfate (50:50, V/V)	48 h NR	RT 4 °C	[94]
RFM	Dried blood samples	1 month	RT 4 °C −20 °C −30 °C	[82]
RFM	Human plasma and saliva	24 h 3 months 3 freeze-thaw cycles	−20 °C −30 °C NR	[62]
RFM <sup>d</sup>	Oral suspensions	7, 14, 28, 56 and 90 days	23–25 °C	[95]
RTG, <i>N</i> -acetyl-retigabine, RFM, STP	Human blood, plasma and serum	24 h 3 freeze-thaw cycles 24, 48 and 72 h	RT −20 °C 4 °C	[96]
PER	Human plasma	24 h post-preparation 2 h 2 freeze-thaw cycles 30 days	4 °C RT −20 °C −20 °C	[77]
PER	Human plasma	48 h 10 days 10 days post-preparation 4 weeks	RT 4 °C 10 °C −20 °C	[97]
PER	Rat plasma and brain <sup>e</sup>	8 h 24 h post-preparative 3 freeze-thaw cycles 28 days	25 °C 10 °C −80 °C −80 °C	[72]
PER	Human plasma	24 h 3 freeze-thaw cycles 3 weeks	RT −20 °C −20 °C	[71]
PER	Human plasma <sup>f</sup>	4 h 24 h 3 freeze-thaw cycles 23 h post-preparation 376 days	RT RT −20 °C 10 °C −20 °C	[76]
PER	Human plasma	24 h 72 h post-preparation 3 freeze-thaw cycles 376 days	RT 10 °C NR −20 °C	[75]

RT: room temperature.

<sup>a</sup> Thermal stress, acid/base forced degradation, oxidative degradation and photodegradation were also evaluated.<sup>b</sup> Retigabine and *N*-acetyl-retigabine stability was also evaluated under presence or absence of *N*-glucuronide-retigabine at different temperatures and time points.<sup>c</sup> Acid and base forced degradation conditions were the only stability conditions tested.<sup>d</sup> Acid/base and oxidative stress conditions were also evaluated.<sup>e</sup> Stability of stock solutions of perampanel in acetonitrile was evaluated after 7 and 28 days at 2–8 °C.<sup>f</sup> Stability of perampanel in standard solutions was evaluated after 37 days at 4 °C and after 17 h at room temperature.



Despite the recent advances in the development of miniaturized techniques for sample preparation, e.g., microextraction by packed sorbent (MEPS) [105] or salting-out assisted liquid-liquid extraction (SALLE) [106,107], conventional techniques as solid-phase extraction (SPE), liquid-liquid extraction (LLE) and protein precipitation (PP) are still the most widely used. Considering the information summarized in Table 4 [40,42–44, 47,50,51,62,71,72,75–83,85,86,90–92,96,97,104,108–116], it is evident that conventional sample preparation approaches (LLE, PP and SPE) continue to be the most applied techniques in studies involving the quantification of STP, RTG, *N*-acetyl-retigabine, RFM and PER.

By analyzing Table 4, it is evident that LLE was the most common extraction procedure used to determine STP in biological samples [42,44,108,109,112]. Also, several studies aiming to determine RTG and *N*-acetyl-retigabine [50], PER [75,76] and RFM [62,81,114] used this sample preparation technique. Instead of following conventional LLE procedure, Perez et al. [50] determined RTG and *N*-acetyl-retigabine in human plasma and urine using an automated LLE procedure based on a 96-well plate format, so that the study could be less time-consuming. This wide use of LLE can be explained by the AEDs lipophilic character that allows their transfer from the aqueous phase (matrix) into the organic phase (solvent). However, since all of them have polar groups in their chemical structures, the organic extraction solvent must be carefully chosen in order to increase analyte extraction efficiency. Considering all the LLE revised techniques, the organic extraction solvents mostly used were ether derivatives, dichloromethane and ethyl acetate, resulting in variable recovery values (Table 4). In fact, Mano et al. [75,76] have developed two different methods for PER quantification in human plasma using different detection systems and, in both, LLE was the selected extraction procedure. In one of the methods, methyl *tert*-butyl ether was used [75] instead of diethyl ether [76], obtaining higher recovery values with methyl *tert*-butyl ether. That suggests differences in the extraction capacity of these two different ether derivatives. However, in some cases, high recovery values need to be sacrificed in order to achieve appropriate selectivity. Globally, considering all the LLE procedures summarized in Table 4, it can be seen that the recovery values obtained are quite variable. In some situations, those values can be so low that discourage the use of LLE comparatively to other extraction procedures such as PP. In fact, a simple, fast and inexpensive sample preparation approach largely used for blood and plasma samples is PP. Acetonitrile and methanol have been shown to be the precipitating agents that provide the best recoveries of analytes. Nevertheless, in some cases, the supernatant may still contain significant interferences of non-precipitated matrix components that can impair the analyte quantification; in these circumstances, PP may be combined with other extraction procedures. As depicted in Table 4, two clear examples of that situation are described by Meirinho et al. [81] and Perez et al. [50]. Both studies applied a PP step previously to LLE procedure in order to obtain cleaner sample extracts, which improved the selectivity for RFM quantification in mouse matrices and for *N*-acetyl-retigabine and RTG quantification in human plasma and urine, respectively. However, by observing Table 4, it is also clear that PP alone is the sample preparation approach most commonly used for PER and RFM determination [46,47,71,72,77–80,82,86,96,97,116]; on the contrary, PP alone was uniquely applied in one assay for the determination of RTG in brain tissue samples [113]. PP was the sample preparation technique employed by Deeb et al. [115] for the simultaneous determination of STP, RTG, *N*-acetyl-retigabine, RFM and seventeen other AEDs in postmortem samples.

Specifically, with regard to precipitating agents, acetonitrile was the most frequently used organic solvent, allowing AEDs

determination within target ranges and minimizing matrix effects [41,43,47,71,72,77,79,82,90,96,97,110,113,116]. Actually, in the study by Paul et al. [72], methanol and acetonitrile were tested and compared as protein precipitating agents, with PER peaks showing better characteristics when acetonitrile was used. Even though methanol is not considered as a better precipitating agent than acetonitrile, it is another organic solvent commonly used in several works to precipitate proteins [78,80,86,115]. Another alternative for PP considered in two different studies was the use of a mixture of acetonitrile and methanol (90:10, V/V), aiming to achieve a better selectivity compared with the use of a single organic solvent [43,46].

SPE is another sample preparation technique, which is of great value in bioanalysis. It provides high recoveries, effective pre-concentration of the analytes and is of easy automation; its key advantage is its ability to remove phospholipids and proteins. In the reviewed SPE techniques that aimed the extraction of *N*-acetyl-retigabine, RTG and RFM from biological matrices, most of the studies referred to the use of cartridges containing silica-based sorbents with ethyl carbon chains (C<sub>2</sub>), octyl carbon chains (C<sub>8</sub>) or octadecyl carbon chains (C<sub>18</sub>) [51,53,83,85,91,92,104]. It is well known that the characteristics of these silica beds increase the retention degree of hydrophobic, non-polar basic analytes. So, once RFM, RTG, STP and PER present weak basic features with clear lipophilic profiles, this could be a probable justification for the frequent use of these cartridges in these analytes' extraction from biological matrices [117]. Differently from the majority of studies that used silica-based columns in conventional SPE format, Bu et al. [92] performed a unique study involving the determination of *N*-acetyl-retigabine in dogs plasma resorting to an Oasis HLB  $\mu$ Elution column integrated in an automated off-line 96-well plate configuration. In fact, this type of SPE columns contain co-polymers in its sorbents that do not require care in the prevention of column dryness; therefore, the critical steps when using Oasis HLB cartridges are sample adsorption and elution rather than conditioning or washing steps, contrary to what happens when silica-based columns are used [118]. Besides this study, other automated SPE systems were also applied, particularly to determine RTG and its main active metabolite [104] and RFM [83,85]. In fact, if automation was applied in all types of sample preparation procedures, it could increase the throughput of bioanalytical methods, making bioanalysis more cost-effective. The most common automated on-line PP, SPE and LLE configuration is the 96-well plate format that allows a faster analysis of the samples [99–101]. Actually, the use of on-line SPE 96-well plates has proven to be a much quicker method, having smaller sorbent bed amounts than traditional SPE cartridges and using fewer amounts of organic solvents. In addition, evaporation or reconstitution steps are not required before sample injection into high-performance liquid chromatography (HPLC) system [83,99]. A clear example of this on-line method was described by Rouan et al. [83], which used a C<sub>18</sub> Empore<sup>®</sup> disc 96-well extraction plate, obtaining satisfactory results with no need to suppress RFM ionization as a consequence of its weak base characteristics. Also, for the determination of RTG, Knebel et al. [104] applied another on-line SPE technique based on a column-switching mechanism that allowed the direct wash of matrix compounds immediately into the waste and right after the sample loading in the column. Then, a valve was switched and the retained analytes were eluted with a strong mobile phase to the analytical chromatographic system. This means that while a sample is being analyzed, another sample is capable of being loaded in the extraction column. So, this assay has shown to be faster and more efficient than off-line SPE [104]. High recoveries were always obtained when using SPE for extracting RTG and RFM from biological samples, presenting values ranging from 63.8% to 106%. Only the study that aimed the determination of *N*-acetyl-retigabine in dog

**Table 4**

Sample pre-treatment and recovery values obtained of the antiepileptic drugs stiripentol (STP), retigabine (RTG) and its active metabolite N-acetyl retigabine, rufinamide (RFM) and perampanel (PER) from biological matrices.

Drug	Matrix	Volume (µL)	Sample preparation	Recovery (%)	Year	Refs.
STP	Human plasma	100	LLE ( <i>tert</i> -butyl methylether)	NR	2017	[42]
STP	Mouse plasma	50–100	LLE (4× diethyl ether)	NR	2017	[108]
STP	Human plasma	10	PP (acetonitrile)	NR	2015	[90]
STP	Rat plasma and brain	50 <sup>a</sup> 500 <sup>b</sup>	LLE ( <i>tert</i> -butylmethylether <sup>a</sup> ; pentane <sup>b</sup> )	NR	2013	[109]
STP	Human serum	100	PP (acetonitrile:methanol, 9:1, V/V)	NR	2012	[43]
STP	Mouse brain	50	PP (acetonitrile)	NR	2010/ 2006	[110,111]
STP	Rat plasma and brain	200 <sup>a</sup> 500 <sup>b</sup>	LLE (ethylacetate)	NR	1994	[112]
STP	Rhesus monkey plasma	200	LLE (ether)	NR	1983	[44]
RTG	Mouse brain	200	PP (acetonitrile)	NR	2018	[113]
RTG	Human plasma	300	SPE (Empore <sup>®</sup> extraction disk cartridges; methanol + water)	95.6–99.8	2018	[91]
RTG, N-acetyl-retigabine	Human plasma and urine	10	PP (acetonitrile) + LLE (diethyl ether)	≥37 (RTG) ≥47.3 (N-acetyl-retigabine)	2015	[50]
N-acetyl-retigabine	Dog plasma	200	SPE (Oasis <sup>®</sup> HLB µElution SPE 96-well; 40:60 acetonitrile:ammonium acetate and 2-propanol)	34.8	2007	[92]
RTG, N-acetyl-retigabine	Human plasma	200	On-line SPE (two LiChroprep RP-2 columns; acetonitrile:2.25 mM ammonium acetate, 55:45, V/V, pH 6)	NR	2000	[104]
RTG	Human plasma	500	SPE (Perisorb RP-8)	≥98	1999	[53]
RTG	Human, dog and rat plasma; human and rat liver slices; dog and rat urine; rat bile	NR	SPE (C <sub>18</sub> Bakerbon; 4× methanol)	NR	1999	[51]
RFM	Mouse plasma, brain, liver and kidney	100	PP (acetonitrile) + LLE (dichloromethane)	73.1–81.9 for plasma; 76.5–82.4 for brain; 73.3–79.8 for liver; 77.4–85.2 for kidney	2019	[81]
RFM	Rat plasma and brain	90	PP (methanol)	87.16–91.03	2018	[80]
RFM	Human plasma	200	PP (acetonitrile)	≥94.94	2016	[96]
RFM	Human plasma and dried blood spots	250	PP (methanol)	95.3	2015	[86]
RFM	Human plasma	50	PP (methanol)	NR	2013	[78]
RFM	Human dried blood spots	NR	PP (water:acetonitrile (30:70, V/V) + 0.05% formic acid solution)	90.6–92.7	2011	[82]
RFM	Human plasma and saliva	NR	LLE (dichloromethane)	94.1 for plasma; 87.2 for saliva	2011	[62]
RFM	Human serum	NR	PP (acetonitrile:methanol, 9:1, V/V)	NR	2011	[40]
RFM	Dog plasma	100	PP (acetonitrile)	NR	2011	[47]
RFM	Human plasma	250	PP (acetonitrile)	97–103	2010	[79]
RFM	Human plasma	100	SPE (3 M Empore C <sub>18</sub> 96-well disc plates; acetonitrile)	NR	2001	[83]
RFM	Human plasma and urine	500	SPE (C <sub>2</sub> Bond Elut; acetonitrile)	88	1995	[85]
RFM	Human plasma	500	LLE (methyl <i>tert</i> -butyl ether:dichloromethane, 2:1, V/V)	55–64.5	1992	[114]
RTG, N-acetyl-retigabine, RFM and STP	Post mortem human blood, plasma and serum	100	PP (methanol)	98–107 (RFM), 71–112 (RTG), 99–109 (STP)	2014	[115]
PER	Human plasma	250	PP (acetonitrile)	98.1–101.3	2018	[77]
PER	Human plasma and serum	100	PP (acetonitrile)	98.1–98.3	2018	[97]
PER	Human plasma and serum	50	PP (acetonitrile)	85.0–108.5	2018	[97]
PER	Rat plasma and brain	50	PP (acetonitrile)	90.21–91.56 for plasma; 86.03–95.86 for brain	2018	[72]
PER	Human plasma	200	PP (acetonitrile)	92.0–96.3	2016	[71]
PER	Human serum	24	PP (acetonitrile)	NR	2016	[116]
PER	Human plasma	1000	LLE (diethyl ether)	60.3–73.2	2015	[76]
PER	Human plasma	100	LLE (methyl <i>tert</i> -butyl ether)	86.3–90.5	2015	[75]

LLE: liquid-liquid extraction; PP: protein precipitation; SA-DLLME: surfactant assisted dispersive liquid-liquid microextraction; SPE: solid-phase extraction; NR: not reported.

<sup>a</sup> Rat plasma.

<sup>b</sup> Rat brain homogenate.

plasma has shown a low recovery (37%), which was explained by the loss of some amount of N-acetyl-retigabine together with N-glucuronide-N-acetyl-retigabine removal [92]. Curiously, to the best of our knowledge, none of the studies aiming to determine STP and PER in biological samples used SPE. An explanation for it could be that both AEDs present a highly lipophilic character, making PP and/or LLE two more promising and economical techniques than SPE.

Considering miniaturized extraction techniques (e.g., MEPS, SALLE), until now, there are no available reports in literature that have used any of these procedures for the analysis of biological

samples containing STP, RTG, N-acetyl-retigabine, RFM or PER. Hence, the application of miniaturized techniques is a field that deserves to be explored. Indeed, the cost reduction when using these miniaturized procedures is their major advantage, as they allow the reduction of the amount of sample and the volume of organic solvents. In addition, simple and fast experimental execution, compatibility with various analytical instruments, the possibility of automation, as well as the chance of combination with other extraction techniques are other advantages [99,105,106].

There are particular situations where biological samples are

only subjected to dilution, filtration and/or centrifugation steps, making it difficult to remove contaminants and other unwanted analytes [99,100]. Based on the gathered information, dilution combined with filtration or centrifugation was only used for determination of RTG, RFM and STP in bulk and pharmaceutical formulations. In these cases, compounds were weighed and, if appropriate, powdered to be dissolved in a selected solvent and, in some situations, diluted, filtered, sonicated and/or centrifuged to be finally injected into the chromatographic system [41,68–70,73,74,84,87,93,94,98,119,120].

Thus, gathering all the collected information about the different preparation procedures used in samples containing STP, RTG, *N*-acetyl-retigabine, RFM or PER, the authors suggest that in less complex matrices, simpler methods such as PP, or even mere dilutions steps and centrifugation/filtration procedures can be used. However, if samples are expected to be more complex (e.g., liver and kidneys), more complex procedures such as SPE, or even a combination of several preparation methods may be necessary to assure suitable selectivity, even with the risk of compromising the analytes recovery.

## 5. LC methods

Over the years, several LC methods have been developed to determine the new AEDs STP, RTG, RFM and PER (Table 5) [40–44,47,50–53,62,68–87,90–98,104,108–116,119,120]. Actually, in the last decade, LC has been the dominant methodology used for analytical and bioanalytical purposes in laboratories worldwide especially in the pharmaceutical field.

To the best of our knowledge, the first HPLC method reported in literature for STP quantification had the purpose to study its complex pharmacokinetic profile in rhesus monkey plasma [44]. Over the times, HPLC has become an important tool to better understand the pharmacokinetic behavior of STP, RTG, RFM and PER, with a particular focus on their metabolism and drug interactions. In fact, several studies have applied HPLC to help elucidate the *N*-glucuronidation [52,53], *N*-acetylation [50,92,104] and other possible RTG metabolic routes [51]. The extensive investigation on the metabolism of RTG is related to the evidence that *N*-acetyl-retigabine presents anticonvulsant activity, which justifies the availability of some HPLC methods specifically developed and validated to quantify this metabolite in biological matrices [50,92,104].

Several HPLC methods have also been employed to support the evaluation of the pharmacokinetics and pharmacological behavior of the AEDs herein addressed (i.e., STP, RTG, RFM and PER). Evaluating the different pharmacological activity and neurotoxicity of the two STP enantiomers [112], studying STP pharmacokinetics and its interactions with other co-administered drugs in pediatric population [42] or in a genetic mouse model [108] and even to study the STP activity in immature rat brains compared with adult rats [109] are examples of different research works supported by HPLC assays. Likewise, research work focused on the assessment of drug interactions of RTG and STP with other possible co-prescribed AEDs using isobolographic analysis [110,111,113,121] is other examples of studies in which HPLC was used as supportive analytical methodology. In addition, LC was also applied to characterize the pharmacokinetics of PER and its brain uptake in a rat species [72] and to study RFM, PER and STP serum concentration dependence in function of the administration route, age, dose, food and co-medication [43,46,96,116,122]. Although several pieces of works have been developed and validated for the determination of STP, RTG, RFM and PER, to the best of our knowledge, up to date, there is only one method using HPLC coupled with tandem mass spectrometry (MS/MS) able to simultaneously determine STP, RTG, *N*-acetyl-retigabine and RFM, together with seventeen other AEDs in

the same chromatographic run, being PER not included in this group. This HPLC assay was developed and validated for routine forensic toxicological analysis, and it was demonstrated to be sensitive, selective and accurately applied to postmortem blood, plasma and serum samples [115]. In all studies here reviewed, different HPLC assays were used, confirming the value and versatility of this analytical methodology to respond to specific needs in different scientific fields.

Throughout drug development programs, a variety of LC methods are also applied in order to guarantee the quality control of pharmaceutical forms, conduct accelerated stability studies and evaluate the presence of impurities. In fact, the study of RTG impurities in bulk drug using HPLC analysis was found to have a relevant role, proving that the impurities found were generated in the last step of RTG synthesis and could be found in different commercial batches [68–70,74,98,120].

Thus, in the next section of this review, the main purpose is to focus on the critical chromatographic variables, in particular the chromatographic columns and respective mobile phases, and also the detection systems that are of the utmost importance for the development and application of LC methods intended for STP, RTG, *N*-acetyl-retigabine, RFM and PER quantification.

### 5.1. Chromatographic columns and mobile phases

During the development of new HPLC methods, steps like column (stationary phase) selection and optimization of the mobile phase composition, pH and flow-rate are critical. The choice of these parameters is mostly based on the desirable peak characteristics (height/area, tailing, shape, symmetry, separation, theoretical plates), run time and solvent consumption [123].

Considering the information summarized in Table 5, the majority of methods reported in literature for STP, RTG, *N*-acetyl-retigabine, RFM and PER determination applied to bulk or pharmaceutical formulations are usually simpler and faster than those applied to biological samples. Additionally, for bulk and pharmaceutical formulations, complex sample preparation procedures and highly sensitive detection methods are not justifiable since the analytes' concentrations are expected to be higher than those expected in biological matrices. Besides, it is not probable to find significant amounts of endogenous interferences that could influence analytes quantification. Methods that quantify the herein studied analytes in bulk and pharmaceutical formulations using HPLC or UHPLC were mostly applied for RTG [68–70,74,98,120] and RFM [84,87,93–95,119], but also, in a smaller proportion, for STP [41,73] (Table 5). In four of the six studies that quantified RTG in bulk and/or pharmaceutical formulations, gradient elution programs were used to pump different mobile phases through the chromatographic system. Acetonitrile was the organic modifier used in all those methods, only modifying the aqueous phase composition (potassium hydrogen phosphate buffer, triethylamine buffer and trifluoroacetic acid in water) pumped through the C<sub>18</sub> silica columns. All the other HPLC or UHPLC methods for the determination of RTG, RFM and STP in bulk and pharmaceutical formulations resorted to isocratic elution, with chromatographic separations also achieved on reversed-phase C<sub>18</sub> bonded to silica columns, with particles size lower in the UHPLC methods compared to the conventional HPLC ones. The only case where a C<sub>18</sub> column was not used was the Saleh et al. [73] study, in which a chiral stationary phase based on polysaccharides, linked to a silica matrix, was employed to obtain the best conditions for STP enantiomers separation. In the isocratic programs applied to bulk and pharmaceutical formulations, acetonitrile was also the organic phase modifier mostly used, followed by methanol. In fact, when compared with methanol, acetonitrile presents some advantages,



**Table 5**

Liquid chromatography techniques and analytical conditions for the determination of stiripentol (STP), retigabine (RTG) and its active metabolite *N*-acetyl retigabine, rufinamide (RFM) and peramppanel (PER) in different matrices.

Drug	Matrix	Technique	Detection	Internal standard	Elution	Column	Mobile phase	Flow rate (mL/min)	Temperature (°C)	Retention time (min)	LLOQ	Year	Refs.
STP	Human plasma	HPLC	UV	3-bromo- <i>N</i> -propylcinnamide	NR	NR	Acetonitrile/water (60:40, V/V)	NR	NR	NR	0.25 mg/L	2017	[42]
STP	Mouse plasma	HPLC	UV (254 nm)	Hexobarbital	Isocratic	Perkin Elmer Brownlee SPP C <sub>18</sub>	Acetonitrile/0.1% trifluoroacetic acid in water (50:50, V/V)	0.5	NR	NR	NR	2017	[108]
STP	Human plasma	HPLC	FLD (Ex/Em: 210/400 nm)	Xanthone	Isocratic	Discovery® HS-C <sub>18</sub> (150 mm × 4.6 mm, 3 μm)	25 mM phosphate buffer pH 2.6/ acetonitrile (43:57, V/V)	1.5	50	4.6	0.05 μg/mL	2015	[90]
STP	Bulk and pharmaceutical formulations	HPLC	DAD (254 nm)	NR	Isocratic	Chiralpak AD-RH (150 mm × 4.6 mm, 5 μm)	Water/acetonitrile (30:70, V/V)	1.0	25	(-)-STP: 6.891; (+)-STP: 5.626	30 μg/mL	2015	[73]
STP	Bulk drug	HPLC	DAD (262.5 nm)	NR	Isocratic	Symmetry C <sub>18</sub> column (75 mm × 4.6 mm, 3.5 μm)	Acetonitrile/50 mM potassium dihydrogen phosphate buffer pH 4.1 (60:40, V/V)	1.0	25 ± 2	1.8	0.242 μg/mL	2014	[41]
STP	Rat plasma and brain	HPLC	UV	AB1191	Isocratic	NR	Acetonitrile/water (60:40, V/V)	NR	NR	NR	NR	2013	[109]
STP	Human serum	HPLC	MS ( <i>m/z</i> 217.3)	10,11-dihydro-CBZ and 5-( <i>p</i> -methylphenyl)-5-phenylhydantoin	Gradient	ZORBAX Eclipse XBD-C <sub>18</sub> (250 mm × 3 mm; 5 μm)	Water/methanol with 5 mM ammonium acetate and 0.1% formic acid	NR	45	NR	0.1 μg/mL	2012	[43]
STP	Mouse brain	HPLC	UV (215 nm)	NR	Isocratic	ESA RP-C <sub>18</sub> 3 μm	50 mM phosphate buffer/acetonitrile (25:75, V/V)	NR	NR	NR	0.1 μg/mL	2010/2006	[110,111]
STP	Rat plasma and brain	HPLC	FLD (Ex/Em: 290/340 nm)	Piperonyl alcohol	Isocratic	Pirkle-type HPLC column (250 mm × 4.6 mm, 5 μm)	Hexane/isopropyl alcohol (97:3, V/V)	2.0	NR	(-)-STP: 7.0; (+)-STP: 8.0	NR	1994	[112]
STP	Rhesus monkey plasma	HPLC	UV (254 nm)	3-bromo- <i>N</i> -propylcinnamide	Isocratic	DuPont Zorbax C <sub>8</sub>	Methanol/water (72:28, 2.5 V/V/V)	NR	NR	7	NR	1983	[44]
RTG	Mouse brain	HPLC	UV (275 nm)	NR	Isocratic	ODS-2 HYPERSIL (150 mm × 4.6 mm, 5 μm)	5 mM triethylammonium phosphate buffer/ methanol/acetonitrile (50:30:20, V/V/V)	1.0	NR	NR	NR	2018	[113]
RTG	Human plasma	HPLC	UV (240 nm)	Flupirtine maleate	Isocratic	C <sub>18</sub> chromolith performance (100 mm × 4.6 mm)	Water/acetonitrile/ methanol (72:18:10, V/V/V) with 0.1% of 85% phosphoric acid	1.5	50	3.2	25 ng/mL	2018	[91]
RTG	Bulk drug	HPLC	DAD (221 nm)	NR	Isocratic	Enable C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Methanol/0.1% triethylamine in water pH 8.0 (60:40, V/V)	1.0	RT	10.2	1.895 μg/mL	2016	[74]
RTG and <i>N</i> -acetyl-retigabine	Human plasma and urine	UHPLC	MS/MS ( <i>m/z</i> 304 → 230 <sup>a</sup> ; <i>m/z</i> 274 → 232 <sup>b</sup> )	[ <sup>2</sup> H <sub>4</sub> ]-RTG and [ <sup>2</sup> H <sub>4</sub> ]- <i>N</i> -acetyl-retigabine	Gradient	ACQUITY UPLC™ C <sub>8</sub> , BEH (50 mm × 2.1 mm, 1.7 μm)	Solution A (10 mM ammonium formate pH 7.9) + solution B (acetonitrile/methanol 90:10, V/V)	0.6	RT	NR	5 ng/mL	2015	[50]
RTG	Bulk drug	HPLC	DAD	NR	Gradient	Agilent Eclipse Plus C <sub>18</sub> (150 mm × 4.6 mm, 5 μm)	0.1% triethylamine in water pH 2.5/ acetonitrile (73:27, V/V)	NR	NR	10	0.02 μg/mL	2015	[69]
RTG	Bulk and pharmaceutical forms	HPLC	UV (254 nm)	NR	Gradient	XBridge C <sub>18</sub> (150 mm × 4.6 mm, 3.5 μm)	10 mM dipotassium hydrogen phosphate in water pH 7.6 + acetonitrile	0.8	25	14	NR	2015	[70]

(continued on next page)

Table 5 (continued)

Drug	Matrix	Technique	Detection	Internal standard	Elution	Column	Mobile phase	Flow rate (mL/min)	Temperature (°C)	Retention time (min)	LLOQ	Year	Refs.
RTG	Bulk drug	HPLC	DAD (250 nm)	NR	Gradient	Agilent C <sub>18</sub> (100 mm × 4.6 mm, 2.7 μm)	0.1% trifluoroacetic acid in water + 0.1% trifluoroacetic acid in acetonitrile	0.8	40	4.5	NR	2014	[98]
RTG	Bulk drug	UHPLC	DAD (247 nm)	NR	Gradient	Ascentis Express C <sub>18</sub> (100 mm × 4.6 mm, 2.7 μm)	10 mM potassium hydrogen phosphate pH 7.5 + acetonitrile	1.2	40	4.2	NR	2014	[68]
RTG	Bulk and pharmaceutical forms	HPLC	UV (302.8 nm)	NR	Isocratic	Welchrom C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	10 mM phosphate buffer pH 3.0/ acetonitrile (50:50, V/V)	1.0	RT	5.67	0.5025 μg/mL	2014	[120]
N-acetyl-retigabine	Dog plasma	HPLC	MS/MS	[ <sup>13</sup> C <sub>6</sub> ]-N-acetyl-retigabine	Gradient	Waters Atlantis C <sub>18</sub> (20 mm × 4.6 mm, 3 μm)	4 mM ammonium acetate as solvent A + acetonitrile as solvent B	1.0	NR	NR	1.0 ng/mL	2007	[92]
RTG	Human plasma and urine	HPLC	UV (220 nm)	NR	Gradient	Kromasil C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	20 mM potassium hydrogen phosphate buffer pH 7.2 + acetonitrile/water (90:10, V/V)	0.5	21–23	NR	NR	2006	[52]
RTG and N-acetyl-retigabine	Human plasma	HPLC	MS/MS ( <i>m/z</i> 274 → 232)	D-10328 (retigabine structural analogue)	Isocratic	LiChrospher 60, RP-Select B (75 mm × 4 mm, 5 μm)	Acetonitrile/2.25 mM ammonium acetate pH 6.0 (55:45, V/V)	0.5	NR	2.11	1 ng/mL	2000	[104]
RTG and N-glucuronide-RTG	Human, rat, and dog plasma; human liver microsomes	HPLC	FLD (Ex/Em: 254/372 nm)	NR	Isocratic	LiChrospher 60 select B1, (120 mm × 4.0 mm, 5 μm) <sup>c</sup> ; Lichroprep RP-2 (40 mm × 25 mm, 5 μm) <sup>d</sup>	75 mM potassium hydrogen phosphate (pH 3.2)/acetonitrile (74:26, V/V) <sup>e</sup> ; 5 mM potassium hydrogen phosphate (pH 3.2)/acetonitrile (76:24, V/V) <sup>f</sup>	1.2	RT	NR	5 pmol	1999	[53]
RTG	Human, dog, and rat plasma; human and rat liver slices; dog and rat urine; rat bile	HPLC	UV (220 nm)	NR	Gradient	Kromasil C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Solvent A (20 mM monopotassium phosphate pH 7.2) + solvent B (acetonitrile/water, 90:10, V/V)	0.5	21–23	NR	NR	1999	[51]
RFM	Mouse plasma, brain, liver, and kidney	HPLC	UV (210 nm)	Chloramphenicol	Isocratic	LiChroCART® Purospher Star column (C <sub>18</sub> , 55 mm × 4 mm; 3 μm)	Water/acetonitrile (82:18, V/V)	1.0	35	3.0	0.1 μg/mL	2019	[81]
RFM	Rat plasma and brain	HPLC	DAD (215 nm)	Piribedil	Isocratic	Phenomenex Kinetex C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	10 mM ammonium acetate buffer pH 4.7/ acetonitrile (84.7:15.3, V/V)	1.0	40	14.6	13.84 ng/mL (plasma); 105.24 ng/g (brain)	2018	[80]
RFM	Human plasma	HPLC	MS/MS	NR	NR	NR	NR	NR	NR	NR	40 ng/mL	2016	[96]
RFM	Human plasma and dried plasma spots	HPLC	UV (210 nm)	Linezolid	Gradient	XBridge C <sub>18</sub> (250 mm × 4.6 mm, 3.5 μm)	Acetonitrile + 50 mM phosphate buffer pH 4.5	1.0	50	18.3	2.4 μg/mL	2015	[86]
RFM	Human plasma	HPLC	MS/MS ( <i>m/z</i> 239 → 127)	Lacosamide	Isocratic	Zorbax SB-C <sub>18</sub> (100 mm × 3 mm, 3.5 μm)	0.1% formic acid in water/methanol (50:50, V/V)	0.3	40	2.6	40 ng/mL	2013	[78]
RFM	Bulk and pharmaceutical forms	HPLC	DAD (215 nm)	NR	Isocratic	C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Water/acetonitrile (40:60, V/V)	0.8	25	NR	1.0 μg/mL	2013	[84]
RFM	Bulk form	HPLC	UV (293 nm)	NR	Isocratic	Phenomenex Luna <sup>R</sup> C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Phosphate buffer/ acetonitrile (60:40, V/V)	1.0	RT	4.717	NR	2013	[93]

RFM	Pharmaceutical dosage forms	UHPLC	DAD (210 nm)	NR	Isocratic	Acquity™ UPLC BEH C <sub>18</sub> (150 mm × 2.1 mm, 1.7 μm)	20 mM potassium dihydrogen orthophosphate pH 4.5/ methanol/ tetrahydrofuran (80:15:5, V/V/V)	0.3	40	4.167	NR	2013 [87]
RFM	Bulk and pharmaceutical forms	HPLC	UV (210 nm)	NR	Isocratic	ODS C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Acetonitrile/100 mM potassium dihydrogen phosphate pH 4.5 (30:70, V/V)	1.0	RT	3.18	4.39 μg/mL	2013 [119]
RFM	Bulk and tablet dosage forms	HPLC	DAD (215 nm)	NR	Isocratic	C <sub>18</sub> (250 mm × 4.6 mm, 5 μm)	Acetonitrile/10 mM tetra butyl ammonium hydrogen sulfate pH 3.37 (50:50, V/V)	1.0	30	3.53	0.873 μg/mL	2012 [94]
RFM	Human dried blood spots	HPLC	MS/MS ( <i>m/z</i> 239.1 → 127.1)	NR	Isocratic	Synergi Fusion-RP 80A (150 mm × 2 mm, 4 μm)	Water/acetonitrile (37:63, V/V) with 0.05% formic acid	0.2	NR	4.0	0.48 μg/mL	2011 [82]
RFM	Human plasma and saliva	HPLC	UV (230 nm)	Metoclopramide	Isocratic	Spherisorb silica (250 mm × 4.6 mm, 5 μm)	Methanol/ dichloromethane/n-hexane (10:25:65, V/V/V) with 6 mL ammonium hydroxide	1.5	30	5.8	0.25 μg/mL	2011 [62]
RFM	Human serum	HPLC	MS ( <i>m/z</i> 239.2)	Cyproheptadine and 10,11-dihydro-CBZ	Gradient	ZORBAX Eclipse XDB-C <sub>18</sub> Solvent Saver (250 mm × 3 mm, 5 μm)	Water/methanol with 5 mM ammonium acetate and 0.1% formic acid	0.5	45	NR	NR	2011 [40]
RFM	Dog plasma	HPLC	DAD (210 nm)	Diadzein	Isocratic	Luna C <sub>18</sub> (2)	Water/acetonitrile/ methanol (65:26.2:8.8, V/V/V)	0.8	NR	NR	0.5 μg/mL	2011 [47]
RFM	Human plasma	HPLC	UV (210 nm)	Citalopram	Isocratic	Synergi Hydro-RP, (250 mm × 4.6 mm, 4 μm)	50 mM potassium dihydrogen phosphate buffer pH 4.5/ acetonitrile/methanol (65:26.2:8.8, V/V/V)	0.8	NR	7.90	2 μg/mL	2010 [79]
RFM	Oral suspension	HPLC	UV (230 nm)	NR	Isocratic	Symmetry C <sub>18</sub> (150 mm × 4.6 mm, 3.5 μm)	Methanol/water (35:65, 0.5 V/V) with 0.1% trifluoroacetic acid	0.5	40	10.9	0.2 mg/mL	2010 [95]
RFM	Human plasma	HPLC	UV (230 nm)	NR	Isocratic	Supelcosil LC <sub>18</sub> (150 mm × 4.6 mm, 5 μm)	Acetonitrile/methanol/ 0.02 M potassium hydrogen phosphate (18:8:74, V/V/V)	1.2 from 0 to 15 min; 2 from 15 to 30 min	RT	NR	50 ng/mL	2001 [83]
RFM	Human plasma and urine	HPLC	UV (230 nm)	CGP 23901	Isocratic	Supelcosil LC <sub>18</sub> (150 mm × 4.6 mm, 5 μm)	Acetonitrile/methanol/ 0.02 M potassium dihydrogen phosphate (18:6:76, V/V/V) <sup>g</sup> [Acetonitrile/(0.015 M tetrabutylammonium hydrogen sulfate-0.015 M tripotassium phosphate-0.003 M phosphoric acid) (14:86, V/V)] <sup>h</sup>	1.2 1.8 <sup>i</sup>	RT	NR	25 ng/mL	1995 [85]
RFM	Human plasma	HPLC	UV (230 nm)	CGP 23901	Isocratic	Hypersil C <sub>18</sub> analytical column (50 mm × 4.6 mm, 5 μm)	0.01 M potassium hydrogen phosphate/ acetonitrile (86:14, V/V)	1.5	RT	3.9	50 ng/mL	1992 [114]

(continued on next page)

Table 5 (continued)

Drug	Matrix	Technique	Detection	Internal standard	Elution	Column	Mobile phase	Flow rate (mL/min)	Temperature (°C)	Retention time (min)	LLOQ	Year	Refs.
RTG, N-acetyl-retigabine, and STP	Postmortem human blood, plasma, and serum	HPLC	MS/MS ( <i>m/z</i> 304.2 → 230.1 <sup>i</sup> ; <i>m/z</i> 239 → 127 <sup>k</sup> ; <i>m/z</i> 217.2 → 159.2 <sup>l</sup> )	Gabapentin-D <sub>10</sub> , tolbutamide and 10,11-dihydro-CBZ	Gradient	Phenomenex Gemini C <sub>18</sub> (150 mm × 2.1 mm, 5 μm)	2 mM ammonium acetate in water + 2 mM ammonium acetate in methanol	0.3	40	NR	0.25 μg/mL (RFM), 0.05 μg/mL (RTG), 0.5 μg/mL (STP)	2014	[115]
PER	Human plasma	HPLC	FLD (Ex/Em: 290/430 nm)	Mirtazapine	Isocratic	Kinetex PFP (100 mm × 4.6 mm, 2.6 μm)	30 mM sodium acetate buffer pH 3.7/ acetonitrile (40:60, V/V)	0.8	NR	2.08	20 ng/mL	2018	[77]
PER	Human plasma and serum	HPLC	FLD (Ex/Em: 290/430 nm)	NR	Isocratic	Poroshell 120 EC-C <sub>18</sub> (50 mm × 4.6 mm, 2.7 μm)	Water/acetonitrile	1.0	NR	4.4	10 ng/mL	2018	[97]
PER	Human plasma and serum	HPLC	MS/MS ( <i>m/z</i> 350.1 → 247.1)	Levetiracetam-D <sub>6</sub>	Gradient	C <sub>18</sub> Hypersil Gold column (50 mm × 2.1 mm, 1.9 μm)	Mobile phase A (water/ formic acid) + mobile phase B (acetonitrile/ formic acid)	0.25 from 0 to 5.12 min; 0.5 from 5.12 to 10.3 min	NR	5.5	2.5 ng/mL	2018	[97]
PER	Rat plasma and brain	UHPLC	Q-TOF-MS ( <i>m/z</i> 350.1288)	Alogliptin	Gradient	Acquity UPLC HSS Cyano column (100 mm × 2.1 mm, 1.8 μm)	Mobile phase A (0.1% formic acid water solution) + mobile phase B (acetonitrile)	0.4	NR	2.95	0.4 ng/mL	2018	[72]
PER	Human plasma	HPLC	UV (320 nm)	Promethazine hydrochloride	Isocratic	Two reverse-phase C <sub>18</sub> Chromolith Performance columns (100 mm × 4.6 mm)	Water/acetonitrile (60:40, V/V) pH 2.3	1.5	50	4.8	25 ng/mL	2016	[71]
PER	Human serum	HPLC	MS	NR	NR	HiQ sil C <sub>18</sub> column	NR	NR	NR	NR	2.0 ng/mL	2016	[116]
PER	Human plasma	HPLC	FLD (Ex/Em: 290/430 nm)	ER-167615	Isocratic	YMC-Pack Pro C <sub>8</sub> (150 mm × 4.6 mm, 5 μm)	Acetonitrile/water/ acetic acid/sodium acetate (840:560:3:1.8, V/V/V/W)	1.0	40	4.3	1.0 ng/mL	2015	[76]
PER	Human plasma	HPLC	MS/MS ( <i>m/z</i> 350.2 → 219.0)	ER-167615	Isocratic	YMC-Pack Pro C <sub>8</sub> (50 mm × 3.0 mm)	Acetonitrile/water/ acetic acid/200 mM ammonium acetate (70:30:0.1:0.1, V/V/V/V)	0.2	40	2.3	0.25 ng/mL	2015	[75]

C<sub>8</sub>: octyl carbon chain; C<sub>18</sub>: octadecyl carbon chain; CBZ: carbamazepine; DAD: diode-array detector; Ex/Em: excitation/emission; FLD: fluorescence detector; Ex/Em: excitation/emission; HPLC: high-performance liquid chromatography; LLOQ: lower limit of quantification; MS: mass spectrometry; MS/MS: tandem mass spectrometry; *m/z*: mass-to-charge ratio; NR: not reported; PER: perampanel; Q-TOF-MS: quadrupole time-of-flight mass spectrometer; RFM: rufinamide; RT: room temperature; RTG: retigabine; STP: stiripentol; UHPLC: ultra-high performance liquid chromatography; UV: ultraviolet.

<sup>a</sup> *m/z* value used to retigabine determination.

<sup>b</sup> *m/z* value used to N-acetyl-retigabine determination.

<sup>c</sup> Column used for human plasma and liver microsomes analysis.

<sup>d</sup> Column used for dog and rat plasma analysis.

<sup>e</sup> Mobile phase used for human plasma and liver microsomes analysis.

<sup>f</sup> Mobile phase used for dog and rat plasma analysis.

<sup>g</sup> Mobile phase used in plasma analysis.

<sup>h</sup> Mobile phase used in urine.

<sup>i</sup> Flow-rate used in urine analysis.

<sup>j</sup> *m/z* value used to retigabine determination.

<sup>k</sup> *m/z* value used to rufinamide determination.

<sup>l</sup> *m/z* value used to stiripentol determination.



in particular, its lower viscosity that reduces the back pressure in the analytical system, its higher elution strength and its lower ultraviolet (UV) absorptivity [123]. However, in a study that aimed the separation of RFM from its three impurities, the use of methanol in the mobile phase allowed a better compound separation and an improved chromatographic resolution compared with the use of acetonitrile [87]. Regarding the aqueous phase composition used in the aforementioned methods, it varied between ammonium sulfate, potassium or sodium phosphate buffers, with pH values ranging from 2.5 [69] to 8.0 [74]. Additionally, triethylamine was added to some aqueous phases aiming to reduce the peak tailing effect [69,74]. In other studies, the aqueous phase consisted solely of water, obtaining, in such cases, a good resolution of the analytes in a wide range of linearity [73,74,84,95].

Concerning the methods applied to biological samples analysis, and bearing in mind their increased complexity when compared with bulk and pharmaceutical formulations, buffers as aqueous phase are usually required to obtain selectivity, accuracy, precision, and sensitivity in shorter run time. The use of an isocratic or a gradient elution program is also a variable of concern during the development of HPLC methods applied to biological samples. According to Table 5, the majority of the HPLC or UHPLC assays developed to determine STP, RTG, RFM and PER in biological matrices applied isocratic elution procedures. In fact, those that applied gradient elution programs either aimed the simultaneous determination of different AEDs in a short run-time [86,97,115,124] or were focused on pharmacokinetic studies involving STP, RTG, *N*-acetyl-retigabine, RFM and PER [43,46,50–52,72,92]. Regarding the type of stationary phase used for biological matrices analysis, Table 5 clearly shows that the chromatographic separation of STP, RTG, RFM and PER has mostly been achieved using porous silica C<sub>18</sub> reversed-phase columns [43,46,47,51,52,71,78–83,85,86,90–92,97,108,110,114–116]. However, due to the short retention time of both PER and IS in Franco et al. [71] method, two reversed-phase C<sub>18</sub> chromolith performance columns were used to separate IS from PER during the analysis of human plasma samples. Particularly, those new chromatographic columns contain a monolith sorbent instead of packed porous particles, creating a uniform surface area that allows a decrease of the chromatographic system back pressure, even with high flow-rates. Furthermore, it enables to increase sensitivity, improve peaks resolution and obtain shorter analytical time [99].

The use of guard-columns is also highly noticeable in many chromatographic methods. The aim is mostly to increase column lifetime by protecting them from quick deactivation and destruction, a situation that is more frequent when dealing with biological samples. Thus, the use of a guard-column is a cost-effective option since the value of a chromatographic column is pronounceably higher than that of the guard-column itself [123]. In fact, the robustness of HPLC methods is frequently compromised by the column aging, usually accompanied by an increase of column pressure and an increase of peak tailing, leading to oscillations in analytes retention time. Therefore, column aging must be monitored and the column must be changed particularly when analytes signals decrease, a situation that is easily observed when low analytes' concentrations are being measured [75].

Although reversed-phase HPLC columns are the most commonly used in LC analysis, among the reviewed methods, two works applied normal phase HPLC columns: one aimed the determination of RFM in human plasma and saliva [62] and the other aimed the characterization of the pharmacokinetics of STP enantiomers in rat plasma and brain [112] (Table 5). This type of HPLC separation is usually appropriate to more polar compounds that are able to be strongly retained in a polar (hydrophilic) stationary phase flushed with non-polar mobile phases. Actually, in both studies, mobile phases containing high percentages of strong

apolar solvents (e.g., hexane and dichloromethane) and specific chromatographic columns with polar silica coatings were used [62,112]. Particularly, Arends et al. [112] used a specific Pirkle-type chromatographic column (4.6 mm × 250 mm, 5 μm; ®-DNB PG (covalent)) that allowed the resolution of enantiomers in a chiral normal phase HPLC method, obtaining acceptable retention times for (–)-STP (7 min) and (+)-STP (8 min) and fulfilling the pharmacokinetic study purpose. Nevertheless, separation with normal phase columns is becoming less used, in that the use of mobile phases containing high percentages of dangerous and polluting organic solvents is one of the main reasons for its discontinuation. Actually, reversed-phase HPLC methods generally use lower percentages of organic solvents in the mobile phase composition, in that the aqueous phase usually composed by water or by an aqueous buffer (Table 5). In fact, for the analysis of biological samples, besides water or water with an acidic modifier or triethylamine, potassium or sodium phosphate buffers are the most used aqueous composition of the mobile phases, their pH values being between 2.5 and 9.9. Still, regarding chromatographic apparatus lifetime and time-consuming procedures, whenever it is possible, the use of water is more desirable than that of buffers. In fact, the studies by both Meirinho et al. [81] and Franco et al. [71] clearly support that statement by testing different buffers and water as aqueous components of mobile phases. Since any of the buffers improved neither resolution nor peak shapes, water solely was finally used as aqueous phase, making mobile phase preparation much simpler. For the analysis of RFM in different biological matrices, most studies used a higher percentage of aqueous than organic solvent in the mobile phase, contrary to what occurs with STP, RTG, *N*-acetyl-retigabine and PER. This difference can be justified by the fact that STP, RTG and PER present a much more hydrophobic character than RFM, as clearly demonstrated by the log P and log D values of each drug stated in Table 2.

Mano et al. [76] made an inter-laboratory cross validation of a method developed for PER quantification in human plasma. This study was carried out in two different laboratories and it was necessary to modify some components of the method, such as column type (C<sub>8</sub> to C<sub>18</sub>) and mobile phase composition (decrease in acetonitrile percentage). That resulted in a marked increase of PER retention time (4.3–11.7 min), which shows the impact of chromatographic conditions in the obtained results. In next section, we will discuss the selection of the analytical detection systems, another key aspect to consider in the development of LC methods.

## 5.2. Detection systems

Different types of detection systems have been used in quantitative HPLC methods, the most commonly being used the UV/diode-array detectors (DAD), the fluorescence detectors and several MS methodologies. UV detectors are the less expensive detection systems but present poor selectivity as a disadvantage. For that, more laborious extraction procedures are required in order to eliminate the interfering endogenous substances that also absorb in the same wavelength range of the target analyte. In those cases and in situations where more than one analyte with different absorption characteristics needs to be quantified, the use of a DAD is of great value by allowing the simultaneous detection of several compounds at different wavelengths in the same chromatographic run [123]. Several studies used this versatile detection system in the analysis of pharmaceutical formulations and biological samples (Table 5). By examining the information summarized in Table 5, it is clear that RFM absorbs UV light at very distinct wavelength ranges than STP and RTG, contrasting with the similarities between UV absorbance of both RTG and STP. This characteristic corroborates the existing similarity in the physicochemical properties of RTG and

STP, in contrast with the ones of RFM. For PER, only one study used UV detection for its quantification in human plasma [71]. However, in this study, the lower limit of quantification (LLOQ) achieved was much higher than those in other methods that used MS or fluorescence detection (Table 5), demonstrating the lower sensitivity of UV detectors than that of the others used. In fact, since PER have native fluorescence, this detection type has been widely used for its quantification in biological matrices [76,77,97]. Fluorescence detection was also used to quantify RTG in human plasma [53] and STP in human and rat plasma and brain [90,112]. Once again, fluorescence detection proved to be highly selective and sensitive since, for the analysis of STP from the same type of biological matrix (i.e., human plasma), the LLOQ obtained by Takahashi et al. [90] was half of the value achieved with an MS detector [43] and five times lower than the LLOQ reached using a UV detector [42]. To apply fluorescence detectors, a specific excitation wavelength must be set to allow the passage of the analyte to a more energetic state that will further enable the isolation of the desired emission wavelength. Then, that emission wavelength will be directed to a photodetector where it is monitored and converted in an electric signal for data processing [123]. The pairs of excitation and emission wavelengths chosen for PER were 290/430 nm [76,77,97], for RTG were 254/372 nm [53] while for STP were 290/340 nm [112] and 210/400 nm [90] (Table 5).

In more recent years, MS and MS/MS detection systems have been becoming widely used in the analysis of pharmaceutical compounds in biological matrices. Between both detectors, MS is simpler than MS/MS since it only measures a single ionic species of each analyte when a specific mass-to-charge ratio ( $m/z$ ) value is applied. In contrast, MS/MS isolates the primary ionic species in order to be fragmented into additional ions and then monitors one or more of these product ions [103,123]. Both systems offer a good selectivity and sensitivity, with MS/MS presenting an additional selectivity generated by the specific analytes' signatures as a result of the precursor to product ions transition [103,123]. Another type of detector that is also based in MS is the mass quadrupole time-of-flight coupled with electrospray ionization (ESI), affording high selectivity, sensitivity and accuracy. This more recent and expensive detector enabled to study PER pharmacokinetics and for the first time its brain disposition [72]. In general, these mass detection systems have been widely applied to support pharmacokinetic studies, allowing the use of sufficient low LLOQ values required for the accurate estimation of elimination pharmacokinetic parameters. According to Table 5, several LC methods using MS or MS/MS detectors have been developed to support pharmacokinetic and pharmacodynamic studies involving STP, RTG and *N*-acetyl-retigabine, RFM and PER [43,46,50,72,92,96,104,116]. Moreover, studies that determine RFM in low sample volumes [78] and in dried blood spots [82], studies that compared fluorescence detection with MS for PER quantification [76,97], and studies that aimed to analyze a high number of AEDs in the same chromatographic run [115] also used these detection systems. Positive-ion detection, which shows protonated molecules, was mostly used for STP, RTG, RFM and PER determination. With that purpose, different ionization sources were applied: negative ESI [78,115], atmospheric pressure ionization (API) [43,46,50,75,82,96], positive-ion atmospheric pressure chemical ionization (APCI) [92,104], and heated electrospray source ionization (HESI) operating in positive-ion mode [97]. When compared with ESI, APCI methods are more powerful in the quantification of moderately polar, or non-polar, low-molecular mass compounds. They also decrease the ionization suppression of analytes caused by endogenous sample interferences, enabling a better sensitivity [104].

When MS or MS/MS detectors used, stable labeled isotopes are frequently used as IS, thus improving accuracy and precision; moreover, their chemical behaviors and ionization properties are

very similar to those of the unlabeled analyte. Resorting to positive ionization in the multiple reaction monitoring transitions, Perez et al. [50] used [ $^2\text{H}_4$ ]-RTG as IS to quantify RTG, and [ $^2\text{H}_4$ ]-*N*-acetyl-retigabine to measure the *N*-acetylated RTG metabolite. Furthermore, a levetiracetam-d6 isotope was used for PER quantification, in which the HESI was applied [97]. So, even though MS and MS/MS detection systems are more expensive than UV or fluorescence detectors, their higher sensitivity is undeniable, thus showing a particular interest in pharmacokinetic studies. This is clearly stated in Mano et al. studies [75,76] that initially developed an MS/MS method, which is a technology not routinely available in many clinical and research laboratories [75]. Accordingly, in order to make PER quantification easier and less expensive, they further developed an HPLC method coupled to fluorescence detection [76]. However, as expected, the LLOQ value of PER with MS/MS detection was lower (0.25 ng/mL) than the corresponding value obtained by fluorescence detection (1 ng/mL); nevertheless, both achieved LLOQs are both consistent with the therapeutic range of PER (Table 1).

## 6. Conclusion

This review gathered important data related to LC methods developed, validated and applied for determination of STP, RTG, *N*-acetyl-retigabine, RFM and PER in different matrices. These analytical tools were developed not only to be applied in quality control studies of pharmaceutical formulations but, mostly, to support pharmacodynamic and pharmacokinetic studies intended to investigate drug interactions, toxicity and therapeutic efficacy of STP, RTG, RFM and PER. This range of applications was only possible because HPLC techniques present several advantages, compared with other analytical methodologies, such as good sensitivity, high resolution, versatility, shorter analysis time per sample, and automation capability. However, in this review, our main focus was on the critical steps that need to be considered during the development of a LC method to achieve the suitable selectivity, sensitivity, accuracy and precision, even when working with very low sample quantities and analytes concentrations. Sample preparation methods, chromatographic columns, mobile phases, and detectors selection are particularly important to successfully achieve all those points. In the methodologies herein reviewed, PP is the predominant technique used to prepare samples containing STP, RTG, *N*-acetyl-retigabine, RFM or PER. Nevertheless, extraction procedures using miniaturized techniques are yet not widely applied for samples containing these drugs. However, depending on the sample aimed to be analyzed, less labor-consuming methods as dilution and centrifugation can be applied in simpler samples but, if the complexity of the matrix increases, it may be necessary to apply more complex sample preparation procedures (e.g., SPE).

Regarding the physicochemical properties of the analytes here addressed, and particularly considering their polarity and hydrophobicity, the majority of reported HPLC methods used a reversed-phase separation, with silica-based  $\text{C}_{18}$  columns as stationary phase. However, comparing the mobile phases used for RFM and for STP, RTG, *N*-acetyl-retigabine and PER, it is clear that, in order to improve RFM detection and separation, a higher percentage of aqueous components is required. This is especially important for new method development, since it is related to the higher hydrophilic character of RFM compared with STP, RTG, *N*-acetyl-retigabine and PER.

MS and MS/MS detection are regarded as the current focus of interest by their clear advantages in terms of selectivity and sensitivity. However, one of their major limitations is the high costs involved. Therefore, UV and fluorescence detection systems continue to be useful approaches for STP, RTG, *N*-acetyl-retigabine,

RFM and PER determination. As STP, RTG and its active metabolite, and PER present native fluorescence, fluorescence detection must be primarily considered in the development of new LC methods for their determination.

Thus, the development of new and more cost-effective methods for research purposes and clinical application is a continuous challenge. Therefore, more work needs to be performed in order to quantify new generation of AEDs such as STP, RTG and its active metabolite *N*-acetyl-retigabine, RFM and PER in an easier and faster manner. The use of different types of samples, such as saliva and urine, as well as the use of simpler and less time-consuming extraction procedures can be a starting point to expand the knowledge on these new AEDs and make available novel and improved bioanalytical tools for application in TDM.

### Declaration of competing interest

The authors declare that there are no conflicts of interest.

### Acknowledgments

This work was supported by Banco Santander/Totta (Portugal) through the fellowship BID/ICI-FCS/CICS/Santander Universidades-UBI/2017, by Foundation for Science and Technology (FCT) through the fellowship SFRH/BD/136028/2018 and by FEDER funds through the POCI - COMPETE 2020 - Operational Program Competitiveness and Internationalization in Axis I (Project No. POCI-01-0145-FEDER-007491) and National Funds by FCT (Project No. UIDB/00709/2020; and Project No. UIDP/00709/2020). The authors also would like to thank the support provided by FEDER funds through the “Programa Operacional do Centro” (Project No. CENTRO-01-0145-FEDER-000013).

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jpha.2020.11.005>.

### References

- [1] E. Ben-Menachem, Medical management of refractory epilepsy-Practical treatment with novel antiepileptic drugs, *Epilepsia* 55 (2014) 3–8.
- [2] S.S. Chung, K. Kelly, C. Schusse, New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy, *J. Epilepsy Res.* 1 (2011) 35–46.
- [3] E. Burakgazi, J.A. French, Seminar in epileptology treatment of epilepsy in adults, *Epileptic Disord.* 18 (2016) 228–239.
- [4] S. De Biase, G.L. Gigli, A. Nilo, et al., Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures, *Expert Opin. Drug Metabol. Toxicol.* 15 (2018) 93–102.
- [5] P. LaPenna, L.M. Tormoehlen, The pharmacology and toxicology of third-generation anticonvulsant drugs, *J. Med. Toxicol.* 13 (2017) 329–342.
- [6] M. Shaju, S. Abraham, Innovations in epilepsy management - an overview, *J. Pharm. Pharmaceut. Sci.* 16 (2013) 564–576.
- [7] M.D. Krasowski, G.A. McMillin, Advances in anti-epileptic drug testing, *Clin. Chim. Acta* 436 (2014) 224–236.
- [8] L. Santulli, A. Coppola, S. Balestrini, et al., The challenges of treating epilepsy with 25 antiepileptic drugs, *Pharmacol. Res.* 107 (2016) 211–219.
- [9] L.G.M. van Rooij, M.P.H. van den Broek, C.M.A. Rademaker, et al., Clinical management of seizures in newborns: diagnosis and treatment, *Pediatr. Drugs* 15 (2013) 9–18.
- [10] S. Stefanović, S.M. Janković, M. Novaković, et al., Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs, *Expert Opin. Drug Metab. Toxicol.* 14 (2018) 153–159.
- [11] M.V. Spanaki, G.L. Barkley, An overview of third-generation antiseizure drugs: clobazam, lacosamide, rufinamide, and vigabatrin, *Neurol. Clin. Pract.* 2 (2012) 236–241.
- [12] M. Mula, Third generation antiepileptic drug monotherapies in adults with epilepsy, *Expert Rev. Neurother.* 16 (2016) 1087–1092.
- [13] J.W. Wheless, B. Vazquez, Rufinamide: a novel broad-spectrum antiepileptic drug, *Epilepsy Current* 10 (2010) 1–6.
- [14] A.G.B. Thompson, H.R. Cock, Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report, *Seizure* 39 (2016) 1–4.
- [15] P. Striano, R. McMurray, E. Santamarina, et al., Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice, *Epileptic Disord.* 20 (2018) 13–29.
- [16] C. Chiron, M. Helias, A. Kaminska, et al., Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? *Epilepsia* 59 (2018) 1705–1717.
- [17] C. Chiron, Stiripentol for the treatment of seizures associated with Dravet syndrome, *Expert Rev. Neurother.* 19 (2019) 301–310.
- [18] S. Jacob, A.B. Nair, An updated overview on therapeutic drug monitoring of recent antiepileptic drugs, *Drugs R. D.* 16 (2016) 303–316.
- [19] K.C. Nickels, E.C. Wirrell, Stiripentol in the management of epilepsy, *CNS Drugs* 31 (2017) 405–416.
- [20] European Medicines Agency, Stiripentol (Diacomit), Summary of product characteristics. [https://www.ema.europa.eu/en/documents/product-information/diacomit-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/diacomit-epar-product-information_en.pdf). (accessed on 5 October, 2020).
- [21] E.P. Yıldız, M.U. Ozkan, T.A. Uzunhan, Efficacy of stiripentol and the clinical outcome in Dravet syndrome, *J. Child Neurol.* 34 (2019) 33–37.
- [22] C.M. Amabile, A. Vasudevan, Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures, *Pharmacotherapy* 33 (2013) 187–194.
- [23] European Medicines Agency, Retigabine (Trobal), Summary of product characteristics. [https://www.ema.europa.eu/en/documents/product-information/trobal-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/trobal-epar-product-information_en.pdf). (accessed on 5 October, 2020).
- [24] O. Takenaka, J. Ferry, K. Saeki, et al., Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures, *Acta Neurol. Scand.* 137 (2017) 400–408.
- [25] P.N. Patsalos, E.P. Spencer, D.J. Berry, Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update, *Ther. Drug Monit.* 40 (2018) 526–548.
- [26] L.A. Rudzinski, N.J. Vélez-Ruiz, E.R. Gedzelman, et al., New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel, *J. Invest. Med.* 64 (2016) 1087–1101.
- [27] A. Gil-Nagel, S. Burd, M. Toledo, et al., A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy, *Seizure* 54 (2018) 61–66.
- [28] T. Tomson, S.I. Johannessen, Therapeutic monitoring of the new antiepileptic drugs, *Eur. J. Clin. Pharmacol.* 55 (2000) 697–705.
- [29] D. Miloshevska, I. Grabnar, T. Vovk, Dried blood spots for monitoring and individualization of antiepileptic drug treatment, *Eur. J. Pharmaceut. Sci.* 75 (2015) 25–39.
- [30] P.N. Patsalos, D.J. Berry, B.F.D. Bourgeois, et al., Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies, *Epilepsia* 49 (2008) 1239–1276.
- [31] S.I. Johannessen, T. Tomson, Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? *Clin. Pharmacokinet.* 45 (2006) 1061–1075.
- [32] P.N. Patsalos, M. Zugman, C. Lake, et al., Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations, *Epilepsia* 58 (2017) 1234–1243.
- [33] A. Reimers, J.A. Berg, Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines, *Drug Des. Dev. Ther.* 12 (2018) 271–280.
- [34] A. Verrotti, G. Prezioso, S. Stagi, et al., Pharmacological considerations in the use of stiripentol for the treatment of epilepsy, *Expert Opin. Drug Metabol. Toxicol.* 12 (2016) 345–352.
- [35] G. Orhan, T. V. Wuttke, A.T. Nies, et al., Retigabine/Ezogabine, a KCNQ/KV7 channel opener: pharmacological and clinical data, *Expert Opin. Pharmacother.* 13 (2012) 1807–1816.
- [36] European Medicines Agency, Rufinamide (Inovelon). Summary of product characteristics. [https://www.ema.europa.eu/en/documents/product-information/inovelon-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/inovelon-epar-product-information_en.pdf). (accessed on 5 October, 2020).
- [37] Food and Drug Administration, Perampanel (fycempa) clinical pharmacology and biopharmaceutics reviews. <https://www.fda.gov/media/84995/download>. (accessed on 5 October, 2020).
- [38] P.N. Patsalos, The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist, *Epilepsia* 56 (2015) 12–27.
- [39] European Medicines Agency, Perampanel (Fycempa), Summary of product characteristics. [https://www.ema.europa.eu/en/documents/product-information/fycempa-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/fycempa-epar-product-information_en.pdf). (accessed on 5 October, 2020).
- [40] E. Perucca, J. Cloyd, D. Critchley, et al., Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy, *Epilepsia* 49 (2008) 1123–1141.
- [41] H.W. Darwish, A.S. Abdelhameed, M.I. Attia, et al., A stability-indicating HPLC-DAD method for determination of stiripentol: development, validation, kinetics, structure elucidation and application to commercial dosage form, *J. Anal. Methods Chem.* 2014 (2014), 638951.
- [42] S. Peigné, S. Chhun, M. Tod, et al., Population pharmacokinetics of stiripentol



- in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy, *Clin. Pharmacokinet.* 57 (2018) 739–748.
- [43] T.W. May, R. Boor, T. Mayer, et al., Concentrations of stiripentol in children and adults with epilepsy, *Ther. Drug Monit.* 34 (2012) 390–397.
- [44] H. Lin, R. Levy, Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey huey-shin, *Epilepsia* 24 (1983) 692–702.
- [45] R.H. Levy, H.S. Lin, H.M. Blehaut, et al., Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity, *J. Clin. Pharmacol.* 23 (1983) 523–533.
- [46] T.W. May, R. Boor, B. Rambeck, et al., Serum concentrations of rufinamide in children and adults with epilepsy, *Ther. Drug Monit.* 33 (2011) 214–221.
- [47] H.M. Wright, A.V. Chen, S.E. Martinez, et al., Pharmacokinetics of oral rufinamide in dogs, *J. Vet. Pharmacol. Therapeut.* 35 (2011) 529–533.
- [48] C.J. Landmark, P.N. Patsalos, Drug interactions involving the new second- and third- generation antiepileptic drugs, *Expert Rev.* 10 (2010) 119–140.
- [49] W. Nasreddine, A. Beydoun, S. Atweh, et al., Emerging drugs for partial onset seizures, *Expert Opin. Emerg. Drugs* 15 (2010) 415–431.
- [50] H.L. Perez, S.L. Boram, C.A. Evans, Development and validation of a quantitative method for determination of retigabine and its N-acetyl metabolite; overcoming challenges associated with circulating labile N-glucuronide metabolites, *Anal. Methods* 7 (2015) 723–735.
- [51] R. Hempel, H. Schupke, P.J. McNeilly, et al., Metabolism of retigabine (D-23129), a novel anticonvulsant, *Drug Metab. Dispos.* 27 (1999) 613–622.
- [52] J. Borlak, A. Gasparic, M. Locher, et al., N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II, *Metabolism* 55 (2006) 711–721.
- [53] A. Hiller, N. Nguyen, C.P. Strassburg, et al., Retigabine N-glucuronidation and its potential role in enterohepatic, *Circulation* 27 (1999) 605–612.
- [54] Stiripentol DrugBank, DB09118, <https://go.drugbank.com/drugs/DB09118>. (accessed on 5 October, 2020).
- [55] R. Lu, S. Liu, Q. Wang, et al., Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement, *Int. J. Nanomed.* 10 (2015) 4937–4946.
- [56] Royal Society of Chemistry, ChemSpider, stiripentol. <http://www.chemspider.com/Chemical-Structure.4470940.html>. (accessed on 5 October, 2020).
- [57] D-23129 I.M. Kapetanovic, C. Rundfeldt, A new anticonvulsant compound, *CNS Drug Rev.* 2 (1996) 308–321.
- [58] G. Blackburn-Munro, W. Dalby-Brown, N.R. Mirza, et al., Retigabine: chemical synthesis to clinical application, *CNS Drug Rev.* 11 (2005) 1–20.
- [59] Ezogabine DrugBank, DB04953, <https://go.drugbank.com/drugs/DB04953>. (accessed on 5 October, 2020).
- [60] Royal Society of Chemistry, ChemSpider, retigabine. <http://www.chemspider.com/Chemical-Structure.108740.html>. (accessed on 5 October, 2020).
- [61] Rufinamide DrugBank, DB06201, <https://go.drugbank.com/drugs/DB06201>. (accessed on 5 October, 2020).
- [62] I. Mazzucchelli, M. Rapetti, C. Fattore, et al., Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva, *Anal. Bioanal. Chem.* 401 (2011) 1013–1021.
- [63] Royal Society of Chemistry, ChemSpider, rufinamide. <http://www.chemspider.com/Chemical-Structure.114471.html>. (accessed on 5 October, 2020).
- [64] M.A. Rogawski, T. Hanada, Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist, *Acta Neurol. Scand.* 127 (2013) 19–24.
- [65] Royal Society of Chemistry, ChemSpider, perampanel. <http://www.chemspider.com/Chemical-Structure.8100130.html>. (accessed on 5 October, 2020).
- [66] R. Zwart, E. Sher, X. Ping, et al., Perampanel, an antagonist of a  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models, *J. Pharmacol. Exp. Therapeut.* 351 (2014) 124–133.
- [67] M. Kumar, N. Reed, R. Liu, et al., Synthesis and evaluation of potent KCNQ2/3-specific channel activators, *Mol. Pharmacol.* 89 (2016) 667–677.
- [68] M. Douša, J. Srbek, S. Rádl, et al., Identification, characterization, synthesis and HPLC quantification of new process-related impurities and degradation products in retigabine, *J. Pharmaceut. Biomed. Anal.* 94 (2014) 71–76.
- [69] X. Wu, F. Shao, C. Tao, et al., Development and validation of a stability indicating HPLC method for the determination of retigabine and its related substances in drug substances, *J. Chin. Pharmaceut. Sci.* 24 (2015) 241–249.
- [70] M. Balaji, K.M. Rao, K. Ramakrishna, et al., Development and validation of gradient stability indicating HPLC method for determining Ezogabine and related substances, *Anal. Chem. Indian J.* 5 (2015) 176–183.
- [71] V. Franco, R. Marchiselli, C. Fattore, et al., Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma, *Ther. Drug Monit.* 38 (2016) 744–750.
- [72] D. Paul, L. Allakonda, A. Sahu, et al., Pharmacokinetics and brain uptake study of novel AMPA receptor antagonist perampanel in SD rats using a validated UHPLC-QTOF-MS method, *J. Pharmaceut. Biomed. Anal.* 149 (2018) 234–241.
- [73] O.A. Saleh, M.F. El-Behairy, A.M. Badawey, et al., Analysis of stiripentol enantiomers on several chiral stationary phases: a comparative study, *Chromatographia* 78 (2015) 267–271.
- [74] N. Tamilselvi, A. Rajasekaran, Stability-indicating RP-HPLC method for the determination of ezogabine and identification of its degradation products, *J. Pharmaceut. Sci. Res.* 8 (2016) 19–23.
- [75] Y. Mano, O. Takenaka, K. Kusano, High-performance liquid chromatography – tandem mass spectrometry method for the determination of perampanel, a novel  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma, *J. Pharmaceut. Biomed. Anal.* 107 (2015) 56–62.
- [76] Y. Mano, O. Takenaka, K. Kusano, HPLC with fluorescence detection assay of perampanel, a novel AMPA receptor antagonist, in human plasma for clinical pharmacokinetic studies, *Biomed. Chromatogr.* 29 (2015) 1589–1593.
- [77] S. Mohamed, C. Candela, R. Riva, et al., Simple and rapid validated HPLC-fluorescence determination of perampanel in the plasma of patients with epilepsy, *Pract. Lab. Med.* 10 (2018) 15–20.
- [78] Z. Gáll, S. Vancea, M.T. Dogaru, et al., Liquid chromatography-mass spectrometric determination of rufinamide in low volume plasma samples, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 940 (2013) 42–46.
- [79] M. Contin, S. Mohamed, C. Candela, et al., Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy, *J. Chromatogr. B* 878 (2010) 461–465.
- [80] A. V Dalvi, C.T. Uppuluri, B.E. Prasanthi, et al., Design of experiments-based RP – HPLC bioanalytical method development for estimation of Rufinamide in rat plasma and brain and its application in pharmacokinetic study, *J. Chromatogr. B* 1102–1103 (2018) 74–82.
- [81] S. Meirinho, M. Rodrigues, A. Fortuna, et al., Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: a tool to support pharmacokinetic studies, *J. Chromatogr. B* 1124 (2019) 340–348.
- [82] G. la Marca, S. Malvagía, L. Filippi, et al., Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method, *J. Pharmaceut. Biomed. Anal.* 54 (2011) 192–197.
- [83] M.C. Rouan, C. Buffet, L. Masson, et al., Practice of solid-phase extraction and protein precipitation in the 96-well format combined with high-performance liquid chromatography-ultraviolet detection for the analysis of drugs in plasma and brain, *J. Chromatogr. B* 754 (2001) 45–55.
- [84] B.S. Kumar, M.M. Annapurna, S. Pavani, Development and validation of a stability indicating RP-HPLC method for the determination of Rufinamide, *J. Pharm. Anal.* 3 (2013) 66–70.
- [85] M.C. Rouan, C. Souppart, L. Alif, et al., Automated analysis of a novel anti-epileptic compound, CGP 33,101, and its metabolite, CGP 47,292, in body fluids by high-performance liquid chromatography and liquid-solid extraction, *J. Chromatogr. B* 667 (1995) 307–313.
- [86] S. Baldelli, D. Cattaneo, L. Giodini, et al., Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots, *Clin. Chem. Lab. Med.* 53 (2015) 435–444.
- [87] M. Geetha, S. Sait, P.S. Reddy, A stability indicating UPLC method for the estimation of related substances, assay and dissolution of rufinamide, *Asian J. Chem.* 25 (2013) 9775–9778.
- [88] Food and Drug Administration, Guidance for Industry bioanalytical method validation guidance for Industry bioanalytical method validation. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>. (accessed on 5 October, 2020).
- [89] European Medicines Agency, Guideline on bioanalytical method validation. [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf). (accessed on 5 October, 2020).
- [90] R. Takahashi, K. Imai, Y. Yamamoto, Determination of stiripentol in plasma by high-performance liquid chromatography with fluorescence detection, *Jpn. J. Pharmaceut. Health Care Sci.* 41 (2015) 643–650.
- [91] V. Franco, K. Baruffi, G. Gatti, et al., A simple and rapid HPLC-UV method for the determination of retigabine in human plasma, *Biomed. Chromatogr.* 32 (2018), e4168.
- [92] W. Bu, M. Nguyen, C. Xu, et al., Determination of N-acetyl retigabine in dog plasma by LC/MS/MS following off-line  $\mu$ Elution 96-well solid phase extraction, *J. Chromatogr. B* 852 (2007) 465–472.
- [93] J. Singh, S. Sangwan, P. Grover, et al., Analytical method development and validation for assay of rufinamide drug, *J. Pharm. Technol. Res. Manag.* 1 (2013) 191–203.
- [94] M. Annapurna, S. Kumar, S.V. Goutam, et al., New stability indicating liquid chromatographic method for the determination of rufinamide in presence of degradant products, *Drug Invent. Today* 2 (2012) 167–174.
- [95] D.J. Hutchinson, Y. Liou, R. Best, et al., Stability of extemporaneously prepared rufinamide oral suspensions, *Ann. Pharmacother.* 44 (2010) 462–465.
- [96] M. Xu, Y. Ni, Y. Zhou, et al., Pharmacokinetics and tolerability of rufinamide following single and multiple oral doses and effect of food on pharmacokinetics in healthy Chinese subjects, *Eur. J. Drug Metab. Pharmacokinet.* 41 (2016) 541–548.
- [97] U. de Garzia, A. D'Urso, F. Ranzato, et al., A liquid chromatography-mass spectrometry assay for determination of perampanel and concomitant antiepileptic drugs in the plasma of patients with epilepsy, compared with a fluorescent HPLC assay, *Ther. Drug Monit.* 40 (2018) 477–485.
- [98] D. Zhang, X. Song, J. Su, Isolation, identification and structure elucidation of two novel process-related impurities of retigabine, *J. Pharmaceut. Biomed. Anal.* 99 (2014) 22–27.
- [99] L. Nováková, H. Vlčková, A review of current trends and advances in modern



- bio-analytical methods: chromatography and sample preparation, *Anal. Chim. Acta* 656 (2009) 8–35.
- [100] S. Soltani, A. Jouyban, Biological sample preparation: attempts on productivity increasing in bioanalysis, *Bioanalysis* 6 (2014) 1691–1710.
- [101] N.Y. Ashri, M. Abdel-Rehim, Sample treatment based on extraction techniques in biological matrices, *Bioanalysis* 3 (2011) 2003–2018.
- [102] A. Bergeron, M. Furtado, F. Garofolo, Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays, *Rapid Commun. Mass Spectrom.* 23 (2009) 1287–1297.
- [103] M. Vogeser, Liquid chromatography-tandem mass spectrometry - application in the clinical laboratory, *Clin. Chem. Lab. Med.* 41 (2003) 117–126.
- [104] N.G. Knebel, S. Grieb, S. Leisenheimer, et al., Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry, *J. Chromatogr. B* 748 (2000) 97–111.
- [105] G. Alves, M. Rodrigues, A. Fortuna, et al., A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis, *Bioanalysis* 5 (2013) 1409–1442.
- [106] I.M. Valente, J.A. Rodrigues, Recent advances in salt-assisted LLE for analyzing biological samples, *Bioanalysis* 7 (2015) 2187–2193.
- [107] Y.Q. Tang, N. Weng, Salting-out assisted liquid – liquid extraction for bioanalysis, *Bioanalysis* 5 (2013) 1583–1598.
- [108] N.A. Hawkins, L.L. Anderson, T.S. Gertler, et al., Screening of conventional anticonvulsants in a genetic mouse model of epilepsy, *Ann. Clin. Transl. Neurol.* 4 (2017) 326–339.
- [109] S. Auvin, C. Lecointe, N. Dupuis, et al., Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain, *Epilepsia* 54 (2013) 2082–2090.
- [110] J.J. Luszczki, N. Ratnaraj, P.N. Patsalos, et al., Characterization of the anti-convulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital and valproate using isobolographic analysis, *Epilepsia* 47 (2006) 1841–1854.
- [111] J.J. Luszczki, M.K. Trojnar, N. Ratnaraj, et al., Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model, *Epilepsy Res.* 90 (2010) 188–198.
- [112] R. Arends, K. Zhang, R. Levy, et al., Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect, *Epilepsy Res.* 18 (1994) 91–96.
- [113] J.J. Luszczki, B. Miziak, Beneficial combination of lacosamide with retigabine in experimental animals: an isobolographic analysis, *Pharmacology* 101 (2018) 22–28.
- [114] L.A. Brunner, M.L. Powell, An automated method for the determination of a new potential antiepileptic agent (CGP 33101) in human plasma using high performance liquid chromatography, *Biomed. Chromatogr.* 6 (1992) 278–282.
- [115] S. Deeb, D.A. McKeown, H.J. Torrance, et al., Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases, *J. Anal. Toxicol.* 38 (2014) 485–494.
- [116] P.N. Patsalos, M. Gougoulaki, J.W. Sander, Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs, *Ther. Drug Monit.* 38 (2016) 358–364.
- [117] H. Engelhardt, C. Blay, J. Saar, Reversed phase chromatography – the mystery of surface silanols, *Chromatographia* 62 (2005) 19–29.
- [118] Corporation Waters, A simplified solid phase extraction (SPE) protocol for bioanalysis using Oasis HLB. <https://www.waters.com/webassets/cms/library/docs/720005140en.pdf>. (accessed on 5 October, 2020).
- [119] K. Harisudha, G. Lavanya, M.M. Eswarudu, et al., RP-HPLC method development and validation for estimation of rufinamide in bulk and its pharmaceutical dosage form, *Int. J. Pharmaceut. Res. Anal.* 2 (2012) 392–397.
- [120] P. Ravisankar, C. Lokapavani, C. Devadasu, et al., An improved RP-HPLC method for the quantitative determination and validation of Retigabine in bulk and Pharmaceutical formulation, *Int. J. Res. Pharm. Sci.* 4 (2014) 21–26.
- [121] J.J. Luszczki, M. Zagaja, B. Miziak, et al., Synergistic interaction of retigabine with levetiracetam in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis, *Pharmacology* 96 (2015) 11–15.
- [122] B.E. Gidal, J. Ferry, O. Majid, et al., Concentration – effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures, *Epilepsia* 54 (2013) 1490–1497.
- [123] L. Snyder, J. Kirkland, *Introduction to Modern Liquid Chromatography*, John Wiley and Sons, New York, 2011.
- [124] M. Mendes, A. Miranda, T. Cova, et al., Modeling of ultra-small lipid nanoparticle surface charge for targeting glioblastoma, *Eur. J. Pharmaceut. Sci.* 117 (2018) 255–269.